Cover
Cover - shares | 3 Months Ended | |
Mar. 31, 2022 | May 16, 2022 | |
Document Type | 10-Q/A | |
Amendment Flag | true | |
Amendment Description | Reliance Global Group, Inc. (the “Company”) filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, with the Securities and Exchange Commission (“SEC”) on May 16, 2022 (the “Original Form 10-Q”). This Amendment No. 1 on Form 10-Q/A (“Amendment No. 1” or “Form 10-Q/A”) is being filed to: | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Mar. 31, 2022 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2022 | |
Current Fiscal Year End Date | --12-31 | |
Entity File Number | 001-40020 | |
Entity Registrant Name | RELIANCE GLOBAL GROUP, INC. | |
Entity Central Index Key | 0001812727 | |
Entity Tax Identification Number | 46-3390293 | |
Entity Incorporation, State or Country Code | FL | |
Entity Address, Address Line One | 300 Blvd. of the Americas | |
Entity Address, Address Line Two | Suite 105 | |
Entity Address, City or Town | Lakewood | |
Entity Address, State or Province | NJ | |
Entity Address, Postal Zip Code | 08701 | |
City Area Code | 732 | |
Local Phone Number | 380-4600 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 755,807 | |
Common Stock [Member] | ||
Title of 12(b) Security | Common Stock | |
Trading Symbol | RELI | |
Security Exchange Name | NASDAQ | |
Series A Warrants [Member] | ||
Title of 12(b) Security | Series A Warrants | |
Trading Symbol | RELIW | |
Security Exchange Name | NASDAQ |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash | $ 5,491,407 | $ 4,136,180 |
Restricted cash | 484,351 | 484,542 |
Accounts receivable | 1,173,383 | 1,024,831 |
Accounts receivable, related parties | 1,642 | 7,131 |
Other receivables | 7,336 | |
Prepaid expense and other current assets | 111,639 | 2,328,817 |
Total current assets | 7,269,758 | 7,981,501 |
Property and equipment, net | 147,140 | 130,359 |
Right-of-use assets | 1,287,636 | 1,067,734 |
Investment in NSURE, Inc. | 1,350,000 | 1,350,000 |
Intangibles, net | 11,895,223 | 7,078,900 |
Goodwill | 29,249,285 | 10,050,277 |
Other non-current assets | 69,784 | 16,792 |
Total assets | 51,268,826 | 27,675,563 |
Current liabilities: | ||
Accounts payable and other accrued liabilities | 1,043,117 | 2,759,160 |
Chargeback reserve | 1,585,435 | |
Other payables | 80,033 | 81,500 |
Current portion of long-term debt | 918,073 | 913,920 |
Current portion of leases payable | 434,045 | 276,009 |
Earn-out liability, current portion | 3,774,411 | 3,297,855 |
Warrant commitment | 37,652,808 | |
Total current liabilities | 7,835,114 | 44,981,252 |
Loans payable, related parties, less current portion | 342,996 | 353,766 |
Long term debt, less current portion | 6,860,467 | 7,085,325 |
Leases payable, less current portion | 871,234 | 805,326 |
Earn-out liability, less current portion | 446,538 | 516,023 |
Warrant liabilities | 23,660,144 | |
Total liabilities | 40,016,493 | 53,741,692 |
Stockholders’ equity (deficit): | ||
Preferred stock, $0.086 par value; 750,000,000 shares authorized and 9,076 and 0 issued and outstanding as of March 31, 2022 and December 31, 2021, respectively | 781 | |
Common stock, $0.086 par value; 133,333,333 shares authorized and 755,806 and 730,407 issued and outstanding as of March 31, 2022 and December 31, 2021, respectively | 64,999 | 62,815 |
Additional paid-in capital | 35,304,698 | 27,329,201 |
Stock subscription receivable | (20,000,000) | |
Accumulated deficit | (24,118,145) | (33,458,145) |
Total stockholders’ equity (deficit) | 11,252,333 | (26,066,129) |
Total liabilities and stockholders’ equity | $ 51,268,826 | $ 27,675,563 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Mar. 31, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.086 | $ 0.086 |
Preferred stock, shares authorized | 750,000,000 | 750,000,000 |
Preferred stock, shares issued | 9,076 | 0 |
Preferred stock, shares outstanding | 9,076 | 0 |
Common stock, par value | $ 0.086 | $ 0.086 |
Common stock, shares authorized | 133,333,333 | 133,333,333 |
Common stock, shares issued | 755,806 | 730,407 |
Common stock, shares outstanding | 755,806 | 730,407 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Revenue | ||
Commission income | $ 4,235,781 | $ 2,323,730 |
Total revenue | 4,235,781 | 2,323,730 |
Operating expenses | ||
Commission expense | 904,156 | 529,472 |
Salaries and wages | 2,082,175 | 918,545 |
General and administrative expenses | 2,453,070 | 1,004,401 |
Marketing and advertising | 587,022 | 23,079 |
Depreciation and amortization | 607,525 | 333,088 |
Total operating expenses | 6,633,948 | 2,808,585 |
Loss from operations | (2,398,167) | (484,855) |
Other expense, net | (107,797) | (129,071) |
Recognition and change in fair value of warrant liabilities | 11,845,964 | |
Total other income (expense) | 11,738,167 | (129,071) |
Net income (loss) | $ 9,340,000 | $ (613,926) |
Basic earnings (loss) per share | $ 2.46 | $ (1.22) |
Diluted earnings (loss) per share | $ (9.69) | $ (1.22) |
Weighted average number of shares outstanding - Basic | 980,569 | 502,825 |
Weighted average number of shares outstanding - Diluted | 1,195,480 | 502,825 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) | Preferred Stock [Member] | Common Stock [Member] | Common stock issuable [Member] | Additional Paid-in Capital [Member] | Subscription receivable [Member] | Retained Earnings [Member] | Total |
Balance at Dec. 31, 2020 | $ 33,912 | $ 24,315 | $ 340,000 | $ 11,898,441 | $ (12,359,680) | $ (63,012) | |
Balance, shares at Dec. 31, 2020 | 395,640 | 282,735 | 1,556 | ||||
Share based compensation | 246,966 | 246,966 | |||||
Shares issued due to private placement | $ 10,320 | 9,098,828 | 9,109,148 | ||||
Shares issued due to private placement, shares | 120,000 | ||||||
Net income (loss) | (613,926) | (613,926) | |||||
Shares issued for services | $ 86 | 90,964 | 91,050 | ||||
Shares issued for services, shares | 1,000 | ||||||
Over-allotment shares from offering, net of offering costs of $250,928 | $ 1,548 | 1,364,825 | 1,366,373 | ||||
Over-allotment shares from offering, net of offering costs, shares | 18,000 | ||||||
Warrants sold during public offering at quoted price | 20,700 | 20,700 | |||||
Shares issued due to conversion of preferred stock | $ (33,812) | $ 22,618 | 11,194 | ||||
Shares issued due to conversion of preferred stock, shares | (394,493) | 262,995 | |||||
Shares issued due to conversion of debt | $ 3,631 | 3,796,369 | 3,800,000 | ||||
Shares issued due to conversion of debt, shares | 42,222 | ||||||
Rounding shares related to initial public offering | |||||||
Rounding shares related to initial public offering, shares | 126 | ||||||
Shares issued pursuant to software purchase | $ 134 | $ (340,000) | 339,866 | 0 | |||
Shares issued pursuant to software purchase, shares | 1,556 | 1,556 | |||||
Shares issued pursuant to software purchase, shares | (1,556) | (1,556) | |||||
Balance at Mar. 31, 2021 | $ 100 | $ 62,652 | 26,868,153 | (12,973,606) | 13,957,299 | ||
Balance, shares at Mar. 31, 2021 | 1,147 | 728,634 | |||||
Balance at Dec. 31, 2021 | $ 62,815 | 27,329,201 | $ (20,000,000) | (33,458,145) | (26,066,129) | ||
Balance, shares at Dec. 31, 2021 | 730,407 | ||||||
Share based compensation | 739,960 | 739,960 | |||||
Shares issued due to private placement | $ 781 | $ 15,313 | (16,043) | 20,000,000 | 20,000,051 | ||
Shares issued due to private placement, shares | 9,076 | 178,059 | |||||
Shares issued pursuant to acquisition of Medigap | $ 3,475 | 4,759,976 | 4,763,451 | ||||
Shares issued pursuant to acquisition of Medigap, shares | 40,402 | ||||||
Exercise of Series A warrants | $ 2,150 | 2,472,850 | 2,475,000 | ||||
Exercise of Series A warrants, shares | 25,000 | ||||||
Issuance of prefunded Series C Warrants in exchange for common shares | $ (18,788) | 18,788 | |||||
Issuance of prefunded Series C Warrants in exchange for common shares, shares | (218,462) | ||||||
Shares issued for vested stock awards | $ 34 | (34) | |||||
Shares issued for vested stock awards, shares | 400 | ||||||
Net income (loss) | 9,340,000 | 9,340,000 | |||||
Balance at Mar. 31, 2022 | $ 781 | $ 64,999 | $ 35,304,698 | $ (24,118,145) | $ 11,252,333 | ||
Balance, shares at Mar. 31, 2022 | 9,076 | 755,806 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) | 3 Months Ended |
Mar. 31, 2021 USD ($) | |
Subsidiary, Sale of Stock [Line Items] | |
Payments of stock issuance costs | $ 1,672,852 |
Over-Allotment Option [Member] | |
Subsidiary, Sale of Stock [Line Items] | |
Payments of stock issuance costs | $ 250,928 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Cash flows from operating activities: | ||
Net income (loss) | $ 9,340,000 | $ (613,926) |
Adjustment to reconcile net income to net cash (used) provided by operating activities: | ||
Depreciation and amortization | 607,528 | 333,087 |
Amortization of debt issuance costs and accretion of debt discount | 6,467 | 5,722 |
Non-cash lease expense | 4,042 | (4,704) |
Stock compensation expense | 739,960 | 352,299 |
Earn-out fair value and write-off adjustments | 407,071 | |
Recognition and change in fair value of warrant liabilities | (11,845,964) | |
Change in operating assets and liabilities: | ||
Accounts payables and other accrued liabilities | (1,715,666) | (893,505) |
Accounts receivable | (148,552) | 181,556 |
Accounts receivable, related parties | 5,489 | (7,131) |
Other receivables | (7,336) | |
Other payables | (1,467) | |
Charge back reserve | 100,962 | |
Other non-current assets | (52,992) | |
Prepaid expense and other current assets | 2,217,178 | |
Net cash used in operating activities | (343,280) | (646,602) |
Cash flows from investing activities: | ||
Purchase of property and equipment | (4,108) | |
Acquisition of business, net of cash acquired | (18,138,750) | |
Purchase of intangibles | (249,235) | |
Net cash used in investing activities | (18,392,093) | |
Cash flows from financing activities: | ||
Principal repayments of debt | (227,172) | (213,994) |
Proceeds from loans payable, related parties | 177,824 | |
Payments of loans payable, related parties | (10,770) | (310,771) |
Proceeds from exercise of warrants into common stock | 2,475,000 | |
Net proceeds from private placement issuance of shares and warrants | 17,853,351 | |
Issuance of common stock | 10,481,938 | |
Net cash provided by financing activities | 20,090,409 | 10,134,997 |
Net increase in cash and restricted cash | 1,355,036 | 9,488,395 |
Cash and restricted cash at beginning of period | 4,620,722 | 529,581 |
Cash and restricted cash at end of period | 5,975,758 | 10,017,976 |
Supplemental disclosure of cash and non-cash investing and financing transactions: | ||
Issuance of Series D Warrants | 6,930,335 | |
Issuance of placement agent warrants | 1,525,923 | |
Conversion of common stock into Series C Warrants | 281,815 | |
Conversion of preferred stock into common stock | 339,264 | |
Cash paid for interest | 105,447 | 116,830 |
Conversion of debt into equity | 3,800,000 | |
Common stock issued pursuant to acquisition | 4,763,451 | |
Common stock issued in lieu of services | 91,050 | |
Issuance of common stock pursuant to the purchase of software | $ 340,000 |
ORGANIZATION AND DESCRIPTION OF
ORGANIZATION AND DESCRIPTION OF BUSINESS | 3 Months Ended |
Mar. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
ORGANIZATION AND DESCRIPTION OF BUSINESS | NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS Reliance Global Group, Inc. (formerly known as Ethos Media Network, Inc.) (“RELI”, “Reliance”, or the “Company”) was incorporated in Florida on August 2, 2013. In September 2018, Reliance Global Holdings, LLC (“Reliance Holdings”, or “Parent Company”), a related party acquired control of the Company. Ethos Media Network, Inc. was then renamed on October 18, 2018. On May 1, 2021, the Company acquired J.P. Kush and Associates, Inc. (“Kush”), an independent healthcare insurance agency (See Note 3). On January 10, 2022, the Company acquired Medigap Healthcare Insurance Company, LLC (“Medigap”), an independent healthcare agency (see Note 3) |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements included herein have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements include the accounting of Reliance Global Group, Inc., and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 included in the Company’s annual report on Form 10-K. Restatement of Previously Issued Financial Statements Subsequent to the Company’s filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, with the Securities and Exchange Commission on May 16, 2022, the Company performed an evaluation of its accounting in connection with the calculation of its basic Earnings Per Share (“EPS”) and diluted EPS for the three months ended March 31, 2022, which concluded on May 12, 2023, and identified errors in such calculation. The errors resulted from improper application of sequencing rules, a miscalculation of the numerator used in the determination of diluted EPS, and a miscalculation of the denominator used in the determination of weighted average shares outstanding for both basic EPS and diluted EPS, and the Company determined that the errors required adjustments of the previously issued financial statements for the quarter ended March 31, 2022. Accordingly, the Company restates its consolidated financial statements for the identified periods in this Form 10-Q/A as outlined further below and in Note 12 Earnings (Loss) Per Share. The following table sets forth the effects of the adjustments on affected items within the Company’s previously reported consolidated statements of operations for the three months ended March 31, 2022, and includes an increase to basic earnings per share in the amount of $ 0.51 3.39 234,447 377,805 SCHEDULE OF PREVIOUSLY REPORTED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2022 As Reported Adjustment As Corrected Basic earnings (loss) per share 1.95 0.51 2.46 Diluted earnings (loss) per share (6.30 ) (3.39 ) (9.69 ) Weighted average number of shares outstanding – Basic 1,215,016 (234,447 ) 980,569 Weighted average number of shares outstanding - Diluted 1,573,285 (377,805 ) 1,195,480 Additionally, please refer to Note 12. Earnings (Loss) Per Share Liquidity As of March 31, 2022, the Company’s reported cash and restricted cash aggregated balance was approximately $ 5,976,000 , current assets were approximately $ 7,270,000 , while current liabilities were approximately $ 7,835,000 . As of March 31, 2022, the Company had a working capital deficit of approximately $ 565,000 and stockholders’ equity of approximately $ 11,252,000 . For the three months ended March 31, 2022, the Company reported loss from operations of approximately $ 2,398,000 , a non-cash, non-operating gain on the recognition and change in fair value of warrant liabilities of approximately $ 11,846,000 , resulting in an overall net income of approximately $ 9,340,000 . The Company reported negative cash flows from operations of approximately $ 343,000 . The Company completed a capital offering in January 2022 that raised net proceeds of approximately $ 17,853,352 . Management believes the company’s financial position and its ability to raise capital to be reasonable and sufficient, providing ample liquidity for the foreseeable future. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Cash Cash consists of checking accounts. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Restricted Cash Restricted cash includes cash pledged as collateral to secure obligations and/or all cash whose use is otherwise limited by contractual provisions. The reconciliation of cash and restricted cash reported within the applicable balance sheet accounts that sum to the total of cash and restricted cash presented in the statement of cash flows is as follows: SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW March 31, 2022 March 31, 2021 Cash $ 5,491,407 $ 9,432,070 Restricted cash 484,351 585,906 Total cash and restricted cash $ 5,975,758 $ 10,017,976 Property and Equipment Property and equipment is stated at cost, less accumulated depreciation. Depreciation is recognized over an asset’s estimated useful life using the straight-line method beginning on the date an asset is placed in service. The Company regularly evaluates the estimated remaining useful lives of the Company’s property and equipment to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Maintenance and repairs are charged to expense as incurred. Estimated useful lives of the Company’s Property and Equipment are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT Useful Life (in years) Computer equipment 5 Office equipment and furniture 7 Leasehold improvements Shorter of the useful life or the lease term Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance includes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels of the fair value hierarchy are as follows: Level 1 — Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities; Level 2 — Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability; and Level 3 — Unobservable inputs for the asset or liability, which include management’s own assumption about the assumptions market participants would use in pricing the asset or liability, including assumptions about risk. As of March 31, 2022 and December 31, 2021 respectively, the Company’s balance sheet includes certain financial instruments, including cash, notes receivables, accounts payable, and short and long-term debt. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amounts of long-term debt approximate their fair value as the variable interest rates are based on a market index. The Company’s Warrant Commitment and warrant liabilities (“Warrant Liabilities”) (see Note 13, Commitments and Contingencies SCHEDULE OF FAIR VALUE OF WARRANT COMMITMENT March 31, 2022 December 31, 2021 Stock price $ 4.31 $ 6.44 Volatility 90 % 90 % Time to expiry 5 5 Dividend yield 0 % 0 % Risk free rate 2.4 % 1.10 % Warrant liability, measurement input The following reconciles the fair values of the liability classified warrants: SCHEDULE OF RECONCILES WARRANT COMMITMENT Series B Warrant Commitment Series B warrant liabilities Placement agent warrants Total March 31, 2022 Series B Warrant Commitment Series B warrant liabilities Placement agent warrants Total Beginning balance $ 37,652,808 $ - $ - $ 37,652,808 Initial recognition - 55,061,119 1,525,923 56,587,042 Unrealized (gain) loss 17,408,311 (31,980,437 ) (946,461 ) (15,518,587 ) Warrants exercised or transferred (55,061,119 ) (55,061,119 ) Ending balance $ - $ 23,080,682 $ 579,462 $ 23,660,144 Series B Warrant Commitment Total December 31, 2021 Series B Warrant Commitment Total Beginning balance $ - $ - Initial recognition 20,244,497 20,244,497 Unrealized (gain) loss 17,408,311 17,408,311 Warrants exercised or transferred - - Ending balance $ 37,652,808 $ 37,652,808 The Company’s contingent accrued earn-out business acquisition consideration liabilities are considered Level 3 fair value liability instruments requiring period fair value assessments. These contingent consideration liabilities were recorded at fair value on the acquisition date and are re-measured quarterly based on the then assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measure is based on significant inputs that are unobservable in the market, they are categorized as Level 3. As of March 31, 2022 and December 31, 2021 respectively, the earn-out liability account balance as reported in the condensed consolidated balance sheets is $ 4,220,949 and $ 3,813,878 . At March 31, 2022 and December 31, 2021, the current portion of the earn-out liability is $ 3,774,411 and $ 3,297,855 , respectively, and the non-current earn out liability, net of current portion was $ 446,538 and $ 516,023 , respectively. In fair valuing these instruments, the income valuation approach is applied and key valuation inputs include contingent payment arrangement terms, projected revenues and cash flows, rate of return, and probability assessments. Undiscounted remaining earn out payments are approximately $ 4,345,000 . For the Company’s earn-out liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3), the following table provides a reconciliation of the beginning and ending balances for each category therein, and gains or losses recognized during the period ended March 31, 2022 and December 31, 2021: SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE March 31, 2022 December 31, 2021 Beginning balance - January 1 $ 3,813,878 $ 2,931,418 Acquisitions and Settlements: - - JP Kush Acquisition - 1,694,166 CCS Write-off - (81,368 ) Altruis partial settlement - (452,236 ) - - Period adjustments: Fair value changes and accretion included in earnings * 407,071 (278,102 ) Ending balance $ 4,220,949 $ 3,813,878 * Recorded as a reduction to general and administrative expenses Quantitative Information about Level 3 Fair Value Measurements Significant unobservable inputs used in the earn-out fair value measurements of the Company’s contingent consideration liabilities designated as Level 3 are as follows: SCHEDULE OF FAIR VALUE MEASUREMENTS March 31, 2022 December 31, 2021 Fair value $ 4,220,949 $ 3,813,878 Valuation technique Discounted cash flow Discounted cash flow Significant unobservable input Projected revenue and probability of achievement Projected revenue and probability of achievement Deferred Financing Costs The Company has recorded deferred financing costs as a result of fees incurred by the Company in conjunction with its debt financing activities. These costs are amortized to interest expense using the straight-line method which approximates the interest rate method over the term of the related debt. As of March 31, 2022 and December 31, 2021, unamortized deferred financing costs were $ 129,791 134,528 Business Combinations The Company accounts for its business combinations using the acquisition method of accounting. Under the acquisition method, assets acquired, liabilities assumed, and consideration transferred are recorded at the date of acquisition at their respective fair values. Definite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration such as earn-outs, the Company records the contingent consideration at fair value at the acquisition date. The Company remeasures fair value as of each reporting date and changes resulting from events after the acquisition date, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value and accretion costs are recognized in earnings. Identifiable Intangible Assets, net Finite-lived intangible assets such as customer relationships assets, trademarks and tradenames are amortized over their estimated useful lives, generally on a straight-line basis for periods ranging from 3 20 Goodwill and other indefinite-lived intangibles The Company records goodwill when the purchase price of a business acquisition exceeds the estimated fair value of net identified tangible and intangible assets acquired. Goodwill is assigned to a reporting unit on the acquisition date and tested for impairment at least annually, or more frequently when events or changes in circumstances indicate that the fair value of a reporting unit has more likely than not declined below its carrying value. Similarly, indefinite-lived intangible assets (if any) other than goodwill are tested annually or more frequently if indicated, for impairment. If impaired, intangible assets are written down to fair value based on the expected discounted cash flows. Financial Instruments The Company evaluates issued financial instruments for classification as either equity or liability based on an assessment of the financial instrument’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the financial instruments issued are freestanding pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and, if applicable whether the financial instruments meet all of the requirements for equity classification under ASC 815, including whether the financial instruments are indexed to the Company’s own Common Stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance and as of each subsequent reporting period end date while the financial instruments are outstanding. Financial instruments that are determined to be liabilities under ASC 480 or ASC 815 are held at their initial fair value and remeasured to fair value at each subsequent reporting date, with changes in fair value recorded as a non-operating, non-cash loss or gain, as applicable. The Company’s financial instruments consist of derivatives related to the warrants issued with the securities purchase agreement as discussed in Note 9, Warrant Liabilities Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606 Revenue from Contracts with Customers The Company’s revenue is primarily comprised of agency commissions earned from insurance carriers (the “Customer” or “Carrier”) related to insurance plans produced through brokering, producing and servicing agreements between insurance carriers and members. The Company defines a “Member” as an individual, family or entity currently covered or seeking insurance coverage. The Company focuses primarily on agency services for insurance products in the “Healthcare” and property and casualty, which includes auto (collectively “P&C”) space, with nominal activity in the life insurance and bond sectors. Healthcare includes plans for individuals and families, Medicare supplements, ancillary and small businesses. The Company also earns revenue in the “Insurance Marketing” space as discussed further below. Consideration for all agency services typically is based on commissions calculated by applying contractual commission rates to policy premiums. For P&C, commission rates are applied to premiums due, whereas for healthcare, commission rates, including override commissions, are applied to monthly premiums received by the Carrier. The Company has two forms of billing practices, “Direct Bill” and “Agency Bill”. With Direct Bill, Carriers bill and collect policy premium payments directly from Members without any involvement from the Company. Commissions are paid to the Company by the Carrier in the following month. With Agency Bill, the Company bills Members premiums due and remits them to Carriers net of commission earned. The following outlines the core principles of ASC 606: Identification of the contract, or contracts, with a customer Identification of the performance obligations in the contract Determination of the transaction price Allocation of the transaction price to the performance obligations in the contract Recognition of revenue when, or as, the Company satisfies a performance obligation Healthcare revenue recognition: The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members. There typically is one performance obligation in contracts with Carriers, to perform agency services that culminate in monthly premium cash collections by the Carrier. The performance obligation is satisfied through a combination of agency services including, marketing carrier’s insurance plans, soliciting Member applications, binding, executing and servicing insurance policies on a continuous basis throughout a policy’s life cycle which includes and culminates with the Customer’s collection of monthly premiums. No commission is earned if cash is not received by Carrier. Thus, commission revenue is earned only after a month’s cash receipts from Members’ dues is received by the Customer. Each month’s Carrier cash collections is considered a separate unit sold and transferred to the Customer i.e., the satisfaction of that month’s performance obligation. Transaction price is typically stated in a contract and usually based on a commission rate applied to Member premiums paid and received by Carrier. The Company generally continues to receive commission payments from Carriers until a Member’s plan is cancelled or the Company terminates its agency agreement with the Carrier. Upon termination, the Company normally will no longer receive any commissions from Carriers even on business still in place. In some instances, trailing commissions could occur which would be recognized similar to other Healthcare revenue. With one performance obligation, allocation of transaction price is normally not necessary. Healthcare typically utilizes the Direct Bill method. The Company recognizes revenue at a point in time, when it satisfies its monthly performance obligation and control of the service transfers to the Customer. Transfer occurs when Member insurance premium cash payments are received by the Customer. The Customer’s receipt of cash is the culmination and complete satisfaction of the Company’s performance obligation, and the earnings process is complete. With Direct Bill, since the amount of monthly Customer cash receipts is unknown to the Company until the following month when notice is provided by Customer to Company, the Company accrues revenue at each period end. Any estimated revenue accrued and recognized at a period-end is trued up for financial reporting per actual revenue earned as provided by the Customer during the following month. P&C revenue recognition The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members. There typically is one performance obligation in contracts with Customers, to perform agency services to solicit, receive proposals and bind insurance policies culminating with policy placement. Commission revenue is earned at the time of policy placement. Transaction price is typically stated in a contract and usually based on commission rates applied to Member premiums due. With one performance obligation, allocation of transaction price is normally not necessary. P&C utilizes both the Agency Bill and Direct Bill methods, depending on the Carrier. The Company recognizes revenue at a point in time when it satisfies its performance obligation and control of the service transfers to the Customer. Transfer occurs when the policy placement process is complete. With both Direct Bill and Agency Bill, the Company accrues commission revenue in the period policies are placed. With Agency Bill, payment is typically received from Members in the month earned, however with Direct Bill, payment is typically received from Carriers in the month subsequent to the commissions being earned. Insurance Marketing revenue recognition: Medigap, a consolidated wholly owned subsidiary of the Company earns commission revenue by selling bound insurance policies with all renewal rights to insurance marketing organizations (the “IM Customer”). The IM Customers utilize innovative actuarial models to value and price policies purchased based on future projections. IM Customers pay a one-time commission per policy purchased to selling agencies based on a pre-agreed formula outlined in the parties’ contractual agreement. Commission payments are subject to chargeback in the event a policy is cancelled or lapses within 3 months of a policy’s effective date or until the first three payments are received from the insured party, depending on the IM Customer Contract. The Company identifies a contract when it has a binding agreement to sell issued insurance policies to the IM Customer. There is one performance obligation in IM Customer contracts, to sell the rights in Company procured issued insurance policies to the IM Customer. The performance obligation is satisfied when the rights to an issued policy have been transferred to the IM Customer. Transaction price is stated in a contract and is a set range of commission amounts based on each policy sold. There are two variable components to consideration received: a) Commissions are only earned once a policy is “Placed”, defined as, an active policy sold to the IM Customer where the IM Customer has received the initial insurance carrier payment with respect to such policy. The Company requires end-user insured parties to pay the initial premium to the insurance carrier upon issuance of a policy. Insurance carrier in turn pays IM Customer its initial payment soon thereafter. Thus, upon sale of an issued policy to IM Customer, the Company has provided a bound issued policy and ensured first premium payment has been completed by insured party. This results in virtual assurance that the IM Customer will receive its initial insurance carrier payment, and it is more than probable that a significant revenue reversal will not occur. The Company thus considers all policies sold to the IM Customer to be Placed for revenue recognition purposes. b) Commission revenue is subject to chargeback in full if a policy is cancelled or lapses within three months from the policy effective date or if the insured party does not make the first three payments of the policy. The Company uses historical activity as well as current factors to estimate the unconstrained variable consideration for recognition per the expected value method. A chargeback reserve liability is credited for the difference between cash consideration received and variable consideration recognized. At each reporting period, the Company remeasures the chargeback reserve liability and recognizes any change as an increase or decrease to the then current period revenue. As of March 31, 2022 and December 31, 2021, the chargeback reserve liability was $ 1,585,435 and $ 0 . With one performance obligation, allocation of transaction price is normally not necessary. The Company recognizes revenue at a point in time when it satisfies its performance obligation and control of an insurance policy transfers to the IM Customer. Transfer of control occurs when the Company submits the Policy to the IM Customer. IM Customers generally pay the Company weekly, and accruals are recorded as necessary at period end. Other revenue policies: When applicable, commission revenue is recognized net of any deductions for estimated commission adjustments due to lapses, policy cancellations, and revisions in coverage. The Company could earn additional revenue from contingent commissions, profit-sharing, override and bonuses based on meeting certain revenue or profit targets established periodically by the Carriers (collectively, “Contingent Commissions”). Contingent Commissions are earned when the Company achieves targets established by Carriers. The Carriers notify the Company when it has achieved the target. The Company recognizes revenue for any Contingent Commissions at the time it is reasonably assured that a significant revenue reversal is not probable, which is generally when a Carrier notifies the Company that it is on track or has earned a Contingent Commission. The following table disaggregates the Company’s revenue by line of business, showing commissions earned: SCHEDULE OF DISAGGREGATION REVENUE Three Months ended March 31, 2022 Medical/Life Property and Casualty Total Regular EBS $ 221,184 $ - $ 221,184 USBA 13,587 - 13,587 CCS/UIS - 43,881 43,881 Montana 506,721 - 506,721 Fortman 332,600 197,260 529,860 Altruis 1,304,872 - 1,304,872 Kush 438,591 - 438,591 Medigap 1,177,085 - 1,177,085 $ 3,994,640 $ 241,141 $ 4,235,781 Three Months ended March 31, 2021 Medical/Life Property and Casualty Contingent commission Total Regular EBS 208,994 - - 208,994 USBA 12,225 - - 12,225 CCS/UIS - 88,818 - 88,818 Montana 535,116 - - 535,116 Fortman 249,801 207,772 - 457,573 Altruis 1,021,004 - - 1,021,004 2,027,140 296,590 - 2,323,730 General and Administrative General and administrative expenses primarily consist of personnel costs for the Company’s administrative functions, professional service fees, office rent, all employee travel expenses, and other general costs. Marketing and Advertising The Company’s direct channel expenses primarily consist of costs for e-mail marketing and newspaper advertisements. The Company’s online advertising channel expense primarily consist of social media ads. Advertising costs for both direct and online channels are expensed as incurred. Stock-Based Compensation Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, based on the terms of the awards. The fair value of the stock-based payments to nonemployees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. As the Reliance Global Group, Inc. Equity Incentive Plan 2019 was adopted in January of 2019, the Company lacks the historical basis to estimate forfeitures and will recognize forfeitures as they occur. Leases The Company recognizes leases in accordance with Accounting Standards Codification Topic 842, “Leases” (“ASC 842” or “ASU 2016-12”). This standard provides enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases are recognized as a single lease expense, generally on a straight-line basis. The Company is the lessee in a contract when the Company obtains the right to use an asset. We currently lease real estate and office space under non-cancelable operating lease agreements. When applicable, consideration in a contract is allocated between lease and non-lease components. Lease payments are discounted using the implicit discount rate in the lease. If the implicit discount rate for the lease cannot be readily determined, the Company uses an estimate of its incremental borrowing rate. The Company did not have any contracts accounted for as finance leases as of March 31, 2021, or 2020. Operating leases are included in the line items right-of-use assets, current portion of leases payable, and leases payable, less current portion in the condensed consolidated balance sheets. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the condensed consolidated balance sheet and are expensed on a straight-line basis over the lease term in the condensed consolidated statement of operations. The Company determines a lease’s term by agreement with lessor and includes lease extension options and variable lease payments when option and/or variable payments are reasonably certain of being exercised or paid. Income Taxes The Company recognizes deferred tax assets and liabilities using enacted tax rates for the effect of temporary differences between the book and tax basis of recorded assets and liabilities. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. In evaluating its ability to recover deferred tax assets within the jurisdiction in which they arise, the Company considers all available positive and negative evidence, including the expected reversals of taxable temporary differences, projected future taxable income, taxable income available via carryback to prior years, tax planning strategies, and results of recent operations. The Company assesses the realizability of its deferred tax assets, including scheduling the reversal of its deferred tax assets and liabilities, to determine the amount of valuation allowance needed. Scheduling the reversal of deferred tax asset and liability balances requires judgment and estimation. The Company believes the deferred tax liabilities relied upon as future taxable income in its assessment will reverse in the same period and jurisdiction and are of the same character as the temporary differences giving rise to the deferred tax assets that will be realized. Seasonality A greater number of the Company’s Medicare-related health insurance plans are sold in the fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage. The majority of the Company’s individual and family health insurance plans are sold in the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of these open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state. Prior Period Adjustments During the June 30, 2021 quarterly financial reporting close process, the Company identified certain immaterial adjustments impacting the prior reporting period. Specifically, the Company identified adjustments to correct asset, liability and equity accounts in relation to historical purchase price allocation accounting, adjustments to true up accounts receivable and retained earnings for certain historical accrued revenues and true up the common stock issuable account. The Company has also separately reclassified its purchase software from property, plant and equipment to intangible assets which had no impact on the condensed consolidated statement of operations. The Company assessed the materiality of the adjustments to prior period financial statements in accordance with S |
STRATEGIC INVESTMENTS AND BUSIN
STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS | 3 Months Ended |
Mar. 31, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS | NOTE 3. STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS As of March 31, 2022, we have acquired nine insurance brokerages (see table below), including both acquisitions of affiliated companies ( i.e. Acquired Date Location Line of Business Status U.S. Benefits Alliance, LLC (USBA) October 24, 2018 Michigan Health Insurance Affiliated Employee Benefit Solutions, LLC (EBS) October 24, 2018 Michigan Health Insurance Affiliated Commercial Solutions of Insurance Agency, LLC (CCS or Commercial Solutions) December 1, 2018 New Jersey P&C – Trucking Industry Unaffiliated Southwestern Montana Insurance Center, Inc. (Southwestern Montana or Montana) April 1, 2019 Montana Group Health Insurance Unaffiliated Fortman Insurance Agency, LLC (Fortman or Fortman Insurance) May 1, 2019 Ohio P&C and Health Insurance Unaffiliated Altruis Benefits Consultants, Inc. (Altruis) September 1, 2019 Michigan Health Insurance Unaffiliated UIS Agency, LLC (UIS) August 17, 2020 New York Health Insurance Unaffiliated J.P. Kush and Associates, Inc. (Kush) May 1, 2021 Michigan Health Insurance Unaffiliated Medigap Healthcare Insurance Company, LLC (Medigap) January 10, 2022 Florida Health Insurance Unaffiliated J.P. Kush and Associates, Inc. Transaction On May 1, 2021, the Company entered into a Purchase Agreement with J.P. Kush and Associates, Inc. whereby the Company shall purchase the business and certain assets noted within the Purchase Agreement (the “Kush Acquisition”) for a total purchase price of $ 3,644,166 . The purchase price was paid with a cash payment of $ 1,900,000 , $ 50,000 in restricted shares of the Company’s common stock, in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and an earn-out payment. The Kush Acquisition was accounted for as a business combination in accordance with the acquisition method under the guidance in ASC 805-10 and 805-20. Accordingly, the total purchase consideration was allocated to intangible assets acquired based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing. The allocation of the purchase price in connection with the Kush Acquisition was calculated as follows: SCHEDULE OF ALLOCATION OF PURCHASE PRICE Description Fair Value Weighted Average Useful Life (Years) Accounts receivable $ 291,414 Trade name and trademarks 685,400 5 Customer relationships 551,000 10 Non-competition agreements 827,800 5 Goodwill 1,288,552 Indefinite Purchase consideration allocated $ 3,644,166 Goodwill of $ 1,288,552 arising from the Kush Acquisition consisted of the value of the employee workforce and the residual value after all identifiable intangible assets were valued. Goodwill recognized pursuant to the Kush Acquisition is currently expected to be deductible for income tax purposes. Total acquisition costs for the Kush Acquisition incurred were $ 58,092 recorded as a component of General and administrative expenses. The approximate revenue and net profit for the acquired business as a standalone entity per ASC 805 from January 1, 2021 to April 30, 2021 was $ 500,000 and $ 219,097 , respectively. Pro Forma Information The results of operations of J.P. Kush and Associates, Inc. will be included in the Company’s consolidated financial statements as of the date of acquisition through the current period end. The following supplemental approximate pro forma combined financial information assumes that the acquisition had occurred at the beginning of the three months ended March 31, 2021: SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION March 31, 2021 Revenue $ 2,695,843 Net Income (Loss) $ (450,868 ) Earnings (Loss) per common share, basic $ (0.90 ) Earnings (Loss) per common share, diluted $ (0.90 ) Medigap Healthcare Insurance Company, LLC Transaction On January 10, 2022, the Company completed the acquisition of all assets of Medigap Healthcare Insurance Company, LLC (“Medigap”) pursuant to which the Company purchased all of the assets of Medigap for a purchase price in the amount of $ 20,096,250 consisting of payment to Medigap of (i) $ 18,138,750 in cash and (ii) issuing to seller 40,402 shares of the Company’s restricted common stock in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended. The purchase price is subject to post-closing adjustment to reconcile certain pre-closing credits and liabilities of the parties. The shares issued to Medigap as part of the purchase price are subject to lock up arrangements pursuant to which 50% of those shares may be sold after the one-year anniversary of the date of Closing the APA and the balance of the shares after the second-year anniversary of the date of closing under the APA. The acquisition of Medigap was accounted for as a business combination in accordance with the acquisition method pursuant to FASB Topic No. 805, Business Combination (ASC 805). Accordingly, the total purchase consideration was allocated to the assets acquired, and liabilities assumed based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing. The preliminary allocation of the purchase price in connection with the acquisition of Medigap was calculated as follows: SCHEDULE OF ALLOCATION OF PURCHASE PRICE Description Fair Value Weighted Average Useful Life (Years) Property, plant and equipment $ 20,666 5 Right-of-use asset 317,787 Trade names 340,000 15 Customer relationships 4,550,000 12 Technology 67,000 3 Backlog 210,000 1 Chargeback reserve (1,484,473 ) Lease liability (317,787 ) Goodwill 19,199,008 Indefinite $ 22,902,201 Trade name was measured at fair value using the relief-from-royalty method under the income approach. Significant inputs used to measure the fair value include an estimate of projected revenue from the trade name, a pre-tax royalty rate of 0.5 11.0 Customer relationships were measured at fair value using the multiple-period excess earnings method under the income approach. Significant inputs used to measure the fair value include an estimate of projected revenue and costs associated with existing customers, and a discount rate of 11.0 Technology was measured at fair value using the cost replacement method of the cost approach. Significant inputs used to measure the fair value include an estimate of cost to replace, an obsolescence rate of 40.3 The value assigned to backlog acquired was estimated based upon the contractual nature of the backlog as of the acquisition date, using the income approach to discount back to present value the cash flows attributable to the backlog, using a discount rate of 11.0 Goodwill of $ 19,199,008 arising from the acquisition of Medigap consisted of the value of the employee workforce and the residual value after all identifiable intangible assets were valued. Goodwill recognized pursuant to the acquisition of Medigap is currently expected to be deductible for income tax purposes. Total acquisition costs for the acquisition of Medigap incurred were $ 94,065 recorded as a component of General and administrative expenses. The approximate revenue and net profit or loss for the acquired business as a standalone entity per ASC 805 from January 10, 2022 to March 31, 2022 was $ 1,177,000 and a loss of $ 148,000 , respectively. Pro Forma Information The results of operations of Medigap will be included in the Company’s consolidated financial statements as of the date of acquisition through the current period end. The following supplemental pro forma approximate combined financial information assumes that the acquisition had occurred at the beginning of the three months ended March 31, 2022 and 2021: SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION March 31, March 31, 2022 2021 Revenue $ 4,659,451 $ 3,602,106 Net Income (Loss) $ 9,355,584 $ (566,903 ) Earnings (Loss) per common share, basic $ 7.65 $ 1.2 ) Earnings (Loss) per common share, diluted $ 1.80 $ 1.2 ) |
INVESTMENT IN NSURE, INC.
INVESTMENT IN NSURE, INC. | 3 Months Ended |
Mar. 31, 2022 | |
Investments, All Other Investments [Abstract] | |
INVESTMENT IN NSURE, INC. | NOTE 4. INVESTMENT IN NSURE, INC. On February 19, 2020, the Company entered into a securities purchase agreement with NSURE, Inc. (“NSURE”) whereas the Company may invest up to an aggregate of $ 20,000,000 5,837,462 35% 1,000,000 291,873 3,000,000 16,000,000 200,000 58,375 100,000 50,000 43,781 1,350,000 On February 10, 2020, the Company issued 3,111 1,000,000 |
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT | 3 Months Ended |
Mar. 31, 2022 | |
Property, Plant and Equipment [Abstract] | |
PROPERTY AND EQUIPMENT | NOTE 5. PROPERTY AND EQUIPMENT Property and equipment consists of the following: SCHEDULE OF PROPERTY AND EQUIPMENTS March 31, December 31, Computer equipment $ 79,379 $ 72,110 Office equipment and furniture 48,616 36,157 Leasehold Improvements 94,486 89,819 Property and equipment 222,481 198,086 Less: Accumulated depreciation (75,341 ) (67,727 ) Property and equipment, net $ 147,140 $ 130,359 Depreciation expense associated with property and equipment, as adjusted to reclassify certain software assets to intangibles, is included within depreciation and amortization in the Company’s condensed consolidated statements of operations and is, $ 7,614 2,658 |
GOODWILL AND OTHER INTANGIBLE A
GOODWILL AND OTHER INTANGIBLE ASSETS | 3 Months Ended |
Mar. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
GOODWILL AND OTHER INTANGIBLE ASSETS | NOTE 6. GOODWILL AND OTHER INTANGIBLE ASSETS Effective January 1, 2020 the Company reorganized its reporting structure into a single operating unit. All of the acquisitions made by the Company are in one industry insurance agencies. These agencies operate in a very similar economic and regulatory environment. The Company has one executive who is responsible for the operations of the insurance agencies. This executive reports directly to the Chief Financial Officer (“CFO”) on a quarterly basis. Additionally, the CFO who is responsible for the strategic direction of the Company reviews the operations of the collective insurance agency business as opposed to an office-by-office view. In accordance with guidance in ASC 350-20-35-45, all the Company’s goodwill will be reassigned to a single reporting unit. For the year ended December 31, 2021 the Company assessed goodwill in accordance with ASC 350-20-35-3, analyzing the relevant qualitative factors. The Company noted that it was not more likely than not that the fair value of the reporting unit is less than its carrying amount, thus determining that the two-step goodwill impairment test was not required. Pursuant to the qualitative assessment, the Company concluded that goodwill was not impaired and this conclusion remains reasonable as of March 31, 2022. The following table rolls forward the Company’s goodwill balance for the periods ending March 31, 2022 and December 31, 2021 As discussed in Note 2 - Prior Period Adjustments (503,345) 9,265,070 8,761,725 SCHEDULE OF IMPAIRMENT OF GOODWILL Goodwill December 31, 2020 $ 8,761,725 Goodwill recognized in connection with Kush acquisition on May 1, 2021 $ 1,288,552 December 31, 2021 $ 10,050,277 Goodwill recognized in connection with Medigap acquisition on January 10, 2022 $ 19,199,008 March 31, 2022 $ 29,249,285 The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of March 31, 2022: SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD Weighted Average Remaining Amortization period (Years) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Trade name and trademarks 5.1 $ 2,117,475 $ (701,666 ) $ 1,415,809 Internally developed software 4.4 881,586 (67,682 ) 813,904 Customer relationships 9.7 8,787,290 (1,239,562 ) 7,547,728 Purchased software 0.3 562,327 (499,846 ) 62,481 Video Production Assets 0.8 50,000 (9,863 ) 40,137 Non-competition agreements 2.6 3,504,809 (1,653,617 ) 1,851,192 Contracts Backlog 0.8 210,000 (46,028 ) 163,972 $ 16,113,487 $ (4,218,264 ) $ 11,895,223 The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2021: Weighted Average Remaining Amortization period (Years) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Trade name and trademarks 3.5 $ 1,777,475 $ (609,822 ) $ 1,167,653 Internally developed software 4.7 595,351 (28,443 ) 566,908 Customer relationships 7.7 4,237,290 (1,048,726 ) 3,188,564 Purchased software 0.6 562,327 (452,985 ) 109,342 Video Production Assets 1.0 20,000 - 20,000 Non-competition agreements 2.9 3,504,809 (1,478,376 ) 2,026,433 $ 10,697,252 $ (3,618,352 ) $ 7,078,900 Amortization expense, as adjusted for certain software reclassifications is, $ 599,911 283,569 The following table reflects expected amortization expense as of March 31, 2022, for each of the following five years and thereafter: SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS Years ending December 31, Amortization Expense 2022 (remainder of year) $ 1,823,253 2023 2,064,243 2024 1,771,983 2025 1,325,184 2026 1,064,552 Thereafter 3,846,008 Total $ 11,895,223 |
ACCOUNTS PAYABLE AND ACCRUED LI
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES | 3 Months Ended |
Mar. 31, 2022 | |
Payables and Accruals [Abstract] | |
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES | NOTE 7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Significant components of accounts payable and accrued liabilities were as follows: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES March 31, December 31, Accounts payable, $ 824,129 $ 547,117 Accrued expenses 116,619 2,170,215 Accrued credit card payables 75,459 36,103 Other accrued liabilities 26,910 5,725 Accounts payable and accrued liabilities $ 1,043,117 $ 2,759,160 |
LONG-TERM DEBT
LONG-TERM DEBT | 3 Months Ended |
Mar. 31, 2022 | |
Debt Disclosure [Abstract] | |
LONG-TERM DEBT | NOTE 8. LONG-TERM DEBT The composition of the long-term debt follows: SCHEDULE OF LONG TERM DEBT March 31, December 31, Oak Street Funding LLC Term Loan for the acquisition of EBS and USBA, net of deferred financing costs of $ 14,051 14,606 $ 470,249 $ 485,317 Oak Street Funding LLC Senior Secured Amortizing Credit Facility for the acquisition of CCS, net of deferred financing costs of $ 16,988 17,626 762,051 785,826 Oak Street Funding LLC Term Loan for the acquisition of SWMT, net of deferred financing costs of $ 10,556 11,027 859,892 884,720 Oak Street Funding LLC Term Loan for the acquisition of FIS, net of deferred financing costs of $ 41,206 42,660 2,164,855 2,226,628 Oak Street Funding LLC Term Loan for the acquisition of ABC, net of deferred financing costs of $ 46,989 48,609 3,521,493 3,616,754 7,778,540 7,999,245 Less: current portion (918,073 ) (913,920 ) Long-term debt $ 6,860,467 $ 7,085,325 Oak Street Funding LLC – Term Loans and Credit Facilities During the year ended December 31, 2018 the Company entered into two debt agreements with Oak Street Funding LLC. On August 1, 2018, EBS and USBA entered into a Credit Agreement with Oak Street Funding LLC (“Oak Street”) whereby EBS and USBA borrowed $ 750,000 Interest accrues at 5.00 22,188 1,025,000 The borrowing rate under the Facility is a variable rate equal to Prime + 1.50 10 25,506 During the year ended December 31, 2019 the Company entered in Credit Agreements with Oak Street on April 1, 2019, May 1, 2019 and September 5, 2019 whereby the Company borrowed a total amount of $ 7,912,000 The borrowing rates under the Facility is a variable rate equal to Prime + 2.00 10 181,125 SCHEDULE OF CUMULATIVE MATURITIES OF LONG-TERM OBLIGATIONS Fiscal year ending December 31, Maturities of 2022 (remainder of year) $ 682,348 2023 957,233 2024 1,010,835 2025 1,069,437 2026 1,130,416 Thereafter 3,058,062 Total 7,908,331 Less debt issuance costs (129,791 ) Total $ 7,778,540 |
Warrant Liabilities
Warrant Liabilities | 3 Months Ended |
Mar. 31, 2022 | |
Warrant Liabilities | |
Warrant Liabilities | NOTE 9. Warrant Liabilities Series B Warrants On December 22, 2021 the Company entered into a securities purchase agreement with several institutional buyers for the purchase and sale of (i) warrants to purchase an aggregate of up to 651,997 shares of the Company’s common stock, par value $ 0.086 per share at an exercise price of $ 61.35 per share, (ii) an aggregate of 178,060 shares of Common Stock, and (iii) 9,076 shares of the Company’s newly-designated Series B convertible preferred stock, par value $ 0.086 per share, with a stated value of $ 1,000 per share, initially convertible into an aggregate of 147,939 shares of Common Stock at a conversion price of $ 61.35 per share, each a freestanding financial instrument, (the “Private Placement”). The aggregate purchase price for the Common Shares, the Preferred Shares and the Warrants is approximately $ 20,000,000 . By entering into the Private Placement on December 22, 2021, the Company entered into a commitment to issue the Common Shares, Preferred Shares and Series B Warrants on the Initial Closing Date for a fixed price and exercise price, as applicable. The commitment to issue Series B Warrants (the “Warrant Commitment”) represents a derivative financial instrument, other than an outstanding share, that, at inception, has both of the following characteristics: (i) embodies a conditional obligation indexed to the Company’s equity. The Company classified the commitment to issue the warrants as a derivative liability because it represents a written option that does not qualify for equity accounting The Company initially measured the derivative liability at its fair value and will subsequently remeasure the derivative liability, at fair value with changes in fair value recognized in earnings. An option pricing model was utilized to calculate the fair value of the Warrant Commitment. The Company initially recorded $ 17,652,808 14,572,126 23,080,682 Placement Agent Warrants In connection with the Private Placement, the Company issued 16,303 five years 61.35 1,525,923 1,525,923 946,461 579,463 |
SIGNIFICANT CUSTOMERS
SIGNIFICANT CUSTOMERS | 3 Months Ended |
Mar. 31, 2022 | |
Risks and Uncertainties [Abstract] | |
SIGNIFICANT CUSTOMERS | NOTE 10. SIGNIFICANT CUSTOMERS Customers and IM Customers representing 10 % or more of total revenue are presented in the table below: SCHEDULE OF CONCENTRATIONS OF REVENUES For the three months ended Insurance Carrier 2022 2021 BlueCross BlueShield 10 % 22 % Priority Health 30 % 35 % LTC Global 25 % - % No other single Customer or IM Customer accounted for more than 10 % of the Company’s commission revenues. The loss of any significant customer, including Priority Health, BlueCross BlueShield and LTC Global could have a material adverse effect on the Company. |
EQUITY
EQUITY | 3 Months Ended |
Mar. 31, 2022 | |
Equity [Abstract] | |
EQUITY | NOTE 11. EQUITY Preferred Stock The Company has been authorized to issue 750,000,000 0.086 Each share of Series A Convertible Preferred Stock shall have ten (10) votes per share and may be converted into ten (10) shares of $ 0.086 The Series B Convertible Preferred Stock shall have no voting rights and may be converted into 16 0.086 In January 2022, the Company issued 9,076 shares of its newly designated Series B convertible preferred stock through the Private Placement for the purpose of raising capital. See Note 9 - Warrant Liabilities As of March 31, 2022 and December 31, 2021, there were 0 shares of Series A Convertible Preferred Stock issued and outstanding, and 9,076 and 0 shares of Series B convertible Preferred Stock, respectively, issued and outstanding. Common Stock The Company has been authorized to issue 133,333,333 0.086 In February 2021, the Company issued 138,000 12,420,000 In February 2021, Reliance Global Holdings, LLC, a related party, converted $ 3,800,000 42,222 90.00 42,222 In May 2021, the Company issued 995 In January 2022, the Company issued 178,059 shares of common stock through the Private Placement for the purpose of raising capital. See Note 9 - Warrant Liabilities In January 2022, the Company issued 40,402 In January 2022, upon agreement with Series A warrant holders, 25,000 warrants were exercised at a price of $ 99.00 25,000 of the Company’s common stock. In March 2022, the Company issued 400 400 stock awards pursuant to an employee agreement. As of March 31, 2022 and December 31, 2021, there were 755,806 730,407 shares of Common Stock outstanding, respectively. Stock Options During the year ended December 31, 2019, the Company adopted the Reliance Global Group, Inc. 2019 Equity Incentive Plan (the “Plan”) under which options exercisable for shares of common stock have been or may be granted to employees, directors, consultants, and service providers. A total of 46,667 shares of common stock are reserved for issuance under the Plan. At March 31, 2022, there were 31,027 shares of common stock reserved for future awards under the Plan. The Company issues new shares of common stock from the shares reserved under the Plan upon exercise of options. The Plan is administered by the Board of Directors (the “Board”). The Board is authorized to select from among eligible employees, directors, and service providers those individuals to whom options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to prescribe, amend, and rescind terms relating to options granted under the Plan. Generally, the interpretation and construction of any provision of the Plan or any options granted hereunder is within the discretion of the Board. The Plan provides that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees, non-employee directors, consultants, and service providers are eligible to receive options which are not ISOs, i.e. “Non-Statutory Stock Options.” The options granted by the Board in connection with its adoption of the Plan were Non-Statutory Stock Options. The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model or the value of the services provided, whichever is more readily determinable. The Black-Scholes option pricing model takes into account, as of the grant date, the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option. The following is a summary of the stock options granted, forfeited or expired, and exercised under the Plan for the three months ended March 31, 2022 and March 31, 2021 respectively: SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding at December 31, 2021 10,928 $ 232.50 2.61 $ - Granted - - - - Forfeited or expired - - - - Exercised - - - - Outstanding at March 31, 2022 10,928 $ 232.50 2.37 - Options Weighted Weighted Aggregate Outstanding at December 31, 2020 15,594 $ 231.45 3.63 $ - Granted - - - - Forfeited or expired - - - - Exercised - - - - Outstanding at March 31, 2021 15,594 $ 228.30 3.38 $ - The following is a summary of the Company’s non-vested stock options as of March 31, 2022 and March 31, 2021 respectively: SCHEDULE OF NON - VESTED STOCK OPTIONS Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Non-vested at December 31, 2021 3,587 $ 227.10 0.90 Granted - - - Vested - - - Forfeited or expired - - - Non-vested at March 31, 2022 3,587 $ 227.10 0.82 Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Non-vested at December 31, 2020 10,636 $ 200.85 2.53 Granted - - - Vested - - - Forfeited or expired - - - Non-vested at March 31, 2021 10,636 $ 223.05 2.34 For the three months ended March 31, 2022, the Board did not approve any options to be issued pursuant to the Plan. As of March 31, 2022, the Company determined that the options granted had a total fair value of $ 2,541,360 63,382 132,364 The intrinsic value is calculated as the difference between the market value and the exercise price of the shares on March 31, 2022. The market value as of March 31, 2022 was $ 64.65 As of March 31, 2021 the Company determined that the options granted had a total fair value of $ 3,386,156 232,684 801,698 The intrinsic value is calculated as the difference between the market value and the exercise price of the shares on March 31, 2021. The market values as of March 31, 2021 was $ 65.40 The Company estimated the fair value of each stock option on the grant date using a Black-Scholes option-pricing model. Black-Scholes option-pricing models require the Company to make predictive assumptions regarding future stock price volatility, recipient exercise behavior, and dividend yield. The Company estimated the future stock price volatility using the historical volatility over the expected term of the option. The expected term of the options was computed by taking the mid-point between the vesting date and expiration date. The following assumptions were used in the Black-Scholes option-pricing model, not accounting for any reverse splits: SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL Three Months Ended March 31, 2022 Three Months Ended March 31, 2021 Exercise price $ 0.16 0.26 $ 0.16 0.26 Expected term 3.25 3.75 3.25 3.75 Risk-free interest rate 0.38% 2.43 % 0.38% 2.43 % Estimated volatility 293.07% 517.13 % 293.07% 517.13 % Expected dividend - - Option price at valuation date $ 0.12 0.27 $ 0.12 0.31 Warrants As a part of the Company’s offering, the Company issued 138,000 Series A Warrants. These warrants are classified as equity warrants because of provisions, pursuant to the warrant agreement, that permit the holder obtain a fixed number of shares for a fixed monetary amount. The warrants are standalone equity securities that are transferable without the Company’s consent or knowledge. The warrants were recorded at a value per the offering of $0.15. The warrants may be exercised at any point from the effective date until the 5 -year anniversary of issuance and are not subject to standard anti-dilution provisions. The Series A Warrants are exercisable at a per share exercise price equal to 110% of the public offering price of one share of common stock and accompanying Series A Warrant, $ 99.00 . Per Common Stock 25,000 of these warrants were exercised in January 2022, resulting in 113,000 Series A warrants issued and outstanding at March 31, 2022. In January 2022, as a result of the issuance of common stock in the January 2022 stock offering and the Medigap Acquisition, the Company received a deficiency notification from Nasdaq indicating violation of Listing Rule 5365(a). As part of its remediation plan, in March 2022, the Company entered into Exchange Agreements with the holders of common stock issued in January 2022. Pursuant to the Exchange Agreements, the Company issued 218,462 Series C prepaid warrants in exchange for 218,462 shares of the Company’s common stock. Additionally, as compensation for entering into the Exchange Agreements, the Company issued 81,500 Series D prepaid warrants to the January 2022 stock offering investors for no additional consideration. The fair value of the Series D prepaid warrants was treated as a deemed dividend and accordingly was treated as a reduction from income available to common stockholders in the calculation of earnings per share. Refer to Note 12, Earnings (Loss) Per Share Equity-based Compensation In 2021, three employees received a signing bonus of shares of the Company’s common stock to be issued after the completion of a service period ranging from one to three years of service. The shares granted in 2021 were valued at $ 110,240 10,328 In 2022, two existing employees were awarded a bonus consisting of shares of the Company’s common stock to be vested immediately. The shares granted in 2022 were valued at $ 666,250 . For the three months ended March 31, 2022, compensation expense on these grants totaled $ 666,250 . As of March 31, 2022 these shares have not been issued. Total stock compensation expense for the three months ended March 31, 2022 and 2021 was $ 739,960 246,966 |
EARNINGS (LOSS) PER SHARE
EARNINGS (LOSS) PER SHARE | 3 Months Ended |
Mar. 31, 2022 | |
Earnings Per Share [Abstract] | |
EARNINGS (LOSS) PER SHARE | NOTE 12. EARNINGS (LOSS) PER SHARE Basic EPS applicable to common stockholders is computed by dividing earnings applicable to common stockholders by the weighted-average number of common shares outstanding. If there is a loss from operations, diluted EPS is computed in the same manner as basic EPS is computed. Similarly, if the Company has net income but its preferred dividend adjustment made in computing income available to common stockholders results in a net loss available to common stockholders, diluted EPS would be computed in the same manner as basic EPS. T he following calculates basic and diluted EPS: SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS Three Months Ended March 31, 2022 March 31, 2021 Net income (loss) $ 9,340,000 $ (613,926 ) Deemed dividend (6,930,335 ) - Net income (loss), numerator, basic computation 2,409,665 (613,926 ) Recognition and change in fair value of warrant liabilities (13,992,664 ) - Net income (loss), numerator, diluted computation $ (11,582,999 ) $ (613,926 ) Weighted average shares - denominator basic computation 980,569 502,825 Effect of Series B warrant liabilities 214,911 - Weighted average shares, as adjusted - denominator diluted computation 1,195,480 502,825 Earnings (loss) per common share - basic $ 2.46 $ (1.22 ) Earnings (loss) per common share - diluted $ (9.69 ) $ (1.22 ) Additionally, the following are considered anti-dilutive securities excluded from weighted-average shares used to calculate diluted net loss per common share: SCHEDULE OF ANTI-DILUTIVE SECURITIES IN WEIGHTED AVERAGE SHARES For the Three Months Ended March 31, 2022 March 31, 2021 Shares subject to outstanding common stock options 10,928 10,928 Shares subject to outstanding Series A warrants 113,000 138,000 Shares subject to unvested stock awards 661 1,200 Shares subject to conversion of Series B preferred stock 147,939 - Weighted-average anti-dilutive securities 147,939 - |
LEASES
LEASES | 3 Months Ended |
Mar. 31, 2022 | |
Leases | |
LEASES | NOTE 13. LEASES Operating Leases ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. The standard requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease, initially measured at the present value of the lease payments. The Company’s leases consist of operating leases on buildings and office space. In accordance with ASU 2016-02, right-of-use assets are amortized over the life of the underlying leases. Lease expense for the three months ended March 31, 2022 and 2021 was $ 145,662 68,268 4.41 5.77 Future minimum lease payment under these operating leases consisted of the following: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT Year ending December 31, Operating Lease 2022 $ 371,025 2023 439,110 2024 172,690 2025 112,923 2026 113,736 Thereafter 268,197 Total undiscounted operating lease payments 1,477,681 Less: Imputed interest 172,402 Present value of operating lease liabilities $ 1,305,279 |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 3 Months Ended |
Mar. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | NOTE 14. COMMITMENTS AND CONTINGENCIES Legal Contingencies The Company is subject to various legal proceedings and claims, either asserted or unasserted, arising in the ordinary course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe the outcome of any of these matters will have a material adverse effect on our business, financial position, results of operations, or cash flows, and accordingly, no legal contingencies are accrued as of March 31, 2022 and December 31, 2021. Litigation relating to the insurance brokerage industry is not uncommon. As such the Company, from time to time have been, subject to such litigation. No assurances can be given with respect to the extent or outcome of any such litigation in the future. Earn-out liabilities The Company has recognized a number of earn-out liabilities resulting from contingent consideration provisions included in business combination agreements. Earn-out consideration is normally earned by acquirees when they meet or exceed pre-agreed upon earnings targets. As discussed in Note 2 - Prior Period Adjustments 300,000 2,631,418 2,931,418 The following outlines changes to the Company’s earn-out liability balances inclusive of accumulated accretion for the respective period ended March 31, 2022 and December 31, 2021: SCHEDULE OF EARN-OUT LIABILITY CCS Fortman Montana Altruis Kush Total Ending balance December 31, 2021 $ - $ 515,308 $ 615,969 $ 992,868 $ 1,689,733 $ 3,813,878 Changes due to fair value adjustments - 29,522 37,741 - 339,808 407,071 Changes due to business combinations Changes due to payments Changes due to write-offs Ending balance March 31, 2022 $ - $ 544,830 $ 653,710 $ 992,868 $ 2,029,541 $ 4,220,949 CCS Fortman Montana Altruis Kush Total Ending balance December 31, 2020 $ 81,368 $ 432,655 $ 522,553 $ 1,894,842 $ - $ 2,931,418 Changes due to business combinations - - - - 1,694,166 1,694,166 Changes due to payments - - - (452,236 ) - (452,236 ) Changes due to fair value adjustments - 82,653 93,416 (449,738 ) (4,433 ) (278,102 ) Changes due to write-offs (81,368 ) - - - - (81,368 ) Ending balance December 31, 2021 $ - $ 515,308 $ 615,969 $ 992,868 $ 1,689,733 $ 3,813,878 COVID-19 pandemic contingencies The spread of the coronavirus (COVID-19) outbreak in the United States has resulted in economic uncertainties which may negatively impact the Company’s business operations. While the disruption is expected to be temporary, there is uncertainty surrounding the duration and extent of the impact. The impact of the coronavirus outbreak on the financial statements cannot be reasonably estimated at this time. Adverse events such as health-related concerns about working in our offices, the inability to travel and other matters affecting the general work environment could harm our business and our business strategy. While we do not anticipate any material impact to our business operations as a result of the coronavirus, in the event of a major disruption caused by the outbreak of pandemic diseases such as coronavirus, we may lose the services of our employees or experience system interruptions, which could lead to diminishment of our business operations. Any of the foregoing could harm our business and delay the implementation of our business strategy and we cannot anticipate all the ways in which the current global health crisis and financial market conditions could adversely impact our business. Management is actively monitoring the global situation on its financial condition, liquidity, operations, industry and workforce. |
INCOME TAXES
INCOME TAXES | 3 Months Ended |
Mar. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | NOTE 15. INCOME TAXES The Company did not have any material uncertain tax positions. The Company’s policy is to recognize interest and penalties accrued related to unrecognized benefits as a component income tax expense (benefit). The Company did not recognize any interest or penalties, nor did it have any interest or penalties accrued as of March 31, 2022 and December 31, 2021. The Company’s income tax provision for interim periods is generally determined using an estimate of the Company’s annual effective tax rate, adjusted for discrete items arising in the quarter. For the three months ended March 31, 2022, however, the Company calculates its income tax expense by applying to any pre-tax loss/income an effective tax rate determined as if the year-to-date period is the annual period. Using this method, for the three months ended March 31, 2022, its estimated annual effective tax rate from continuing operation was 0 % and the resulting income tax expense was $ 0 . We believe that, at this time, this method for determining the effective tax rate is more reliable than projecting an annual effective tax rate due to the uncertainty of estimating annual pre-tax loss/income under the impact of the COVID-19 pandemic. The Company’s estimated annual effective tax rate differs from the U.S. statutory tax rate primarily due to a valuation allowance recorded against the deferred tax assets. Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using applicable tax rates. A valuation allowance is recorded against deferred tax assets if it is not more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the deferred tax assets in future, the Company has recorded a full valuation allowance against its net deferred tax assets. The calculation of the Company’s tax liabilities also involves assessment of uncertainties in the application of complex tax laws and regulations in the applicable jurisdictions, and a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of technical merits. The Company’s policy is to record interest and penalties accrued related to unrecognized benefits as a component of income tax expense (benefit). The Company did not have any material uncertain tax positions, and there were no amounts for penalties or interest recorded as of March 31, 2022. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its positions. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 3 Months Ended |
Mar. 31, 2022 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS | NOTE 16. RELATED PARTY TRANSACTIONS The Company entered into a Loan Agreement with Reliance Global Holdings, LLC, a related party under common control. There is no term to the loan, and it bears no interest. Repayment will be made as the Company has business cash flows. The proceeds from the various loans were utilized to fund the acquisitions of USBA, EBS, CCS, SWMT, Fortman , Altruis, and UIS. As of March 31, 2022, and December 31, 2021 the related party loan payable was $ 343,000 and $ 354,000 respectively. At March 31, 2022 and December 31, 2021, Reliance Holdings owned approximately 36 33 |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 3 Months Ended |
Mar. 31, 2022 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | NOTE 17. SUBSEQUENT EVENTS On April 26, 2022, the Company entered into an agreement (the “APA”) with Barra &Associates, LLC (“Seller”) pursuant to which the Company purchased all of the assets of Barra & Associates, LLC for a purchase price in the amount of $ 7,500,000 to be paid to Barra in cash, with $ 6,000,000 paid at closing, $ 1,125,000 payable in six months from closing, and a final earnout of $ 375,000 payable over two years from closing based upon meeting stated milestones. The APA contains standard, commercial representations and warranties and covenants. Closing of the acquisition (“Barra Acquisition”) occurred simultaneously with the execution of the APA. The source of the cash payment is $ 980,000 in cash from the Company’s funds and $ 6,520,000 in funds borrowed from Oak Street Lending (“Loan”), the Company’s existing lender pursuant to a Fifth Amendment to Credit Agreement and Promissory Note, of even date. The purchase price is subject to post-closing adjustment to reconcile certain pre-closing credits and liabilities of the parties. On April 26, 2022, the Company closed on a debt agreement with Oak Street to borrow a principal amount of $ 6,520,000 from Oak Street under a term loan to fund the Barra Acquisition pursuant to a Fifth Amendment to Credit Agreement and Promissory Note, of even date. The borrowing rate under the facility is variable and equal to Prime + 2.50%, except that during the initial period of the loan, the rate is Prime + 2.75%. The loan matures 10 |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Principles of Consolidation | Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements included herein have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements include the accounting of Reliance Global Group, Inc., and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 included in the Company’s annual report on Form 10-K. |
Restatement of Previously Issued Financial Statements | Restatement of Previously Issued Financial Statements Subsequent to the Company’s filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, with the Securities and Exchange Commission on May 16, 2022, the Company performed an evaluation of its accounting in connection with the calculation of its basic Earnings Per Share (“EPS”) and diluted EPS for the three months ended March 31, 2022, which concluded on May 12, 2023, and identified errors in such calculation. The errors resulted from improper application of sequencing rules, a miscalculation of the numerator used in the determination of diluted EPS, and a miscalculation of the denominator used in the determination of weighted average shares outstanding for both basic EPS and diluted EPS, and the Company determined that the errors required adjustments of the previously issued financial statements for the quarter ended March 31, 2022. Accordingly, the Company restates its consolidated financial statements for the identified periods in this Form 10-Q/A as outlined further below and in Note 12 Earnings (Loss) Per Share. The following table sets forth the effects of the adjustments on affected items within the Company’s previously reported consolidated statements of operations for the three months ended March 31, 2022, and includes an increase to basic earnings per share in the amount of $ 0.51 3.39 234,447 377,805 SCHEDULE OF PREVIOUSLY REPORTED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2022 As Reported Adjustment As Corrected Basic earnings (loss) per share 1.95 0.51 2.46 Diluted earnings (loss) per share (6.30 ) (3.39 ) (9.69 ) Weighted average number of shares outstanding – Basic 1,215,016 (234,447 ) 980,569 Weighted average number of shares outstanding - Diluted 1,573,285 (377,805 ) 1,195,480 Additionally, please refer to Note 12. Earnings (Loss) Per Share |
Liquidity | Liquidity As of March 31, 2022, the Company’s reported cash and restricted cash aggregated balance was approximately $ 5,976,000 , current assets were approximately $ 7,270,000 , while current liabilities were approximately $ 7,835,000 . As of March 31, 2022, the Company had a working capital deficit of approximately $ 565,000 and stockholders’ equity of approximately $ 11,252,000 . For the three months ended March 31, 2022, the Company reported loss from operations of approximately $ 2,398,000 , a non-cash, non-operating gain on the recognition and change in fair value of warrant liabilities of approximately $ 11,846,000 , resulting in an overall net income of approximately $ 9,340,000 . The Company reported negative cash flows from operations of approximately $ 343,000 . The Company completed a capital offering in January 2022 that raised net proceeds of approximately $ 17,853,352 . Management believes the company’s financial position and its ability to raise capital to be reasonable and sufficient, providing ample liquidity for the foreseeable future. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. |
Cash | Cash Cash consists of checking accounts. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. |
Restricted Cash | Restricted Cash Restricted cash includes cash pledged as collateral to secure obligations and/or all cash whose use is otherwise limited by contractual provisions. The reconciliation of cash and restricted cash reported within the applicable balance sheet accounts that sum to the total of cash and restricted cash presented in the statement of cash flows is as follows: SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW March 31, 2022 March 31, 2021 Cash $ 5,491,407 $ 9,432,070 Restricted cash 484,351 585,906 Total cash and restricted cash $ 5,975,758 $ 10,017,976 |
Property and Equipment | Property and Equipment Property and equipment is stated at cost, less accumulated depreciation. Depreciation is recognized over an asset’s estimated useful life using the straight-line method beginning on the date an asset is placed in service. The Company regularly evaluates the estimated remaining useful lives of the Company’s property and equipment to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Maintenance and repairs are charged to expense as incurred. Estimated useful lives of the Company’s Property and Equipment are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT Useful Life (in years) Computer equipment 5 Office equipment and furniture 7 Leasehold improvements Shorter of the useful life or the lease term |
Fair Value of Financial Instruments | Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance includes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels of the fair value hierarchy are as follows: Level 1 — Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities; Level 2 — Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability; and Level 3 — Unobservable inputs for the asset or liability, which include management’s own assumption about the assumptions market participants would use in pricing the asset or liability, including assumptions about risk. As of March 31, 2022 and December 31, 2021 respectively, the Company’s balance sheet includes certain financial instruments, including cash, notes receivables, accounts payable, and short and long-term debt. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amounts of long-term debt approximate their fair value as the variable interest rates are based on a market index. The Company’s Warrant Commitment and warrant liabilities (“Warrant Liabilities”) (see Note 13, Commitments and Contingencies SCHEDULE OF FAIR VALUE OF WARRANT COMMITMENT March 31, 2022 December 31, 2021 Stock price $ 4.31 $ 6.44 Volatility 90 % 90 % Time to expiry 5 5 Dividend yield 0 % 0 % Risk free rate 2.4 % 1.10 % Warrant liability, measurement input The following reconciles the fair values of the liability classified warrants: SCHEDULE OF RECONCILES WARRANT COMMITMENT Series B Warrant Commitment Series B warrant liabilities Placement agent warrants Total March 31, 2022 Series B Warrant Commitment Series B warrant liabilities Placement agent warrants Total Beginning balance $ 37,652,808 $ - $ - $ 37,652,808 Initial recognition - 55,061,119 1,525,923 56,587,042 Unrealized (gain) loss 17,408,311 (31,980,437 ) (946,461 ) (15,518,587 ) Warrants exercised or transferred (55,061,119 ) (55,061,119 ) Ending balance $ - $ 23,080,682 $ 579,462 $ 23,660,144 Series B Warrant Commitment Total December 31, 2021 Series B Warrant Commitment Total Beginning balance $ - $ - Initial recognition 20,244,497 20,244,497 Unrealized (gain) loss 17,408,311 17,408,311 Warrants exercised or transferred - - Ending balance $ 37,652,808 $ 37,652,808 The Company’s contingent accrued earn-out business acquisition consideration liabilities are considered Level 3 fair value liability instruments requiring period fair value assessments. These contingent consideration liabilities were recorded at fair value on the acquisition date and are re-measured quarterly based on the then assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measure is based on significant inputs that are unobservable in the market, they are categorized as Level 3. As of March 31, 2022 and December 31, 2021 respectively, the earn-out liability account balance as reported in the condensed consolidated balance sheets is $ 4,220,949 and $ 3,813,878 . At March 31, 2022 and December 31, 2021, the current portion of the earn-out liability is $ 3,774,411 and $ 3,297,855 , respectively, and the non-current earn out liability, net of current portion was $ 446,538 and $ 516,023 , respectively. In fair valuing these instruments, the income valuation approach is applied and key valuation inputs include contingent payment arrangement terms, projected revenues and cash flows, rate of return, and probability assessments. Undiscounted remaining earn out payments are approximately $ 4,345,000 . For the Company’s earn-out liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3), the following table provides a reconciliation of the beginning and ending balances for each category therein, and gains or losses recognized during the period ended March 31, 2022 and December 31, 2021: SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE March 31, 2022 December 31, 2021 Beginning balance - January 1 $ 3,813,878 $ 2,931,418 Acquisitions and Settlements: - - JP Kush Acquisition - 1,694,166 CCS Write-off - (81,368 ) Altruis partial settlement - (452,236 ) - - Period adjustments: Fair value changes and accretion included in earnings * 407,071 (278,102 ) Ending balance $ 4,220,949 $ 3,813,878 * Recorded as a reduction to general and administrative expenses |
Quantitative Information about Level 3 Fair Value Measurements | Quantitative Information about Level 3 Fair Value Measurements Significant unobservable inputs used in the earn-out fair value measurements of the Company’s contingent consideration liabilities designated as Level 3 are as follows: SCHEDULE OF FAIR VALUE MEASUREMENTS March 31, 2022 December 31, 2021 Fair value $ 4,220,949 $ 3,813,878 Valuation technique Discounted cash flow Discounted cash flow Significant unobservable input Projected revenue and probability of achievement Projected revenue and probability of achievement |
Deferred Financing Costs | Deferred Financing Costs The Company has recorded deferred financing costs as a result of fees incurred by the Company in conjunction with its debt financing activities. These costs are amortized to interest expense using the straight-line method which approximates the interest rate method over the term of the related debt. As of March 31, 2022 and December 31, 2021, unamortized deferred financing costs were $ 129,791 134,528 |
Business Combinations | Business Combinations The Company accounts for its business combinations using the acquisition method of accounting. Under the acquisition method, assets acquired, liabilities assumed, and consideration transferred are recorded at the date of acquisition at their respective fair values. Definite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration such as earn-outs, the Company records the contingent consideration at fair value at the acquisition date. The Company remeasures fair value as of each reporting date and changes resulting from events after the acquisition date, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value and accretion costs are recognized in earnings. |
Identifiable Intangible Assets, net | Identifiable Intangible Assets, net Finite-lived intangible assets such as customer relationships assets, trademarks and tradenames are amortized over their estimated useful lives, generally on a straight-line basis for periods ranging from 3 20 |
Goodwill and other indefinite-lived intangibles | Goodwill and other indefinite-lived intangibles The Company records goodwill when the purchase price of a business acquisition exceeds the estimated fair value of net identified tangible and intangible assets acquired. Goodwill is assigned to a reporting unit on the acquisition date and tested for impairment at least annually, or more frequently when events or changes in circumstances indicate that the fair value of a reporting unit has more likely than not declined below its carrying value. Similarly, indefinite-lived intangible assets (if any) other than goodwill are tested annually or more frequently if indicated, for impairment. If impaired, intangible assets are written down to fair value based on the expected discounted cash flows. |
Financial Instruments | Financial Instruments The Company evaluates issued financial instruments for classification as either equity or liability based on an assessment of the financial instrument’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the financial instruments issued are freestanding pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and, if applicable whether the financial instruments meet all of the requirements for equity classification under ASC 815, including whether the financial instruments are indexed to the Company’s own Common Stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance and as of each subsequent reporting period end date while the financial instruments are outstanding. Financial instruments that are determined to be liabilities under ASC 480 or ASC 815 are held at their initial fair value and remeasured to fair value at each subsequent reporting date, with changes in fair value recorded as a non-operating, non-cash loss or gain, as applicable. The Company’s financial instruments consist of derivatives related to the warrants issued with the securities purchase agreement as discussed in Note 9, Warrant Liabilities |
Revenue Recognition | Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606 Revenue from Contracts with Customers The Company’s revenue is primarily comprised of agency commissions earned from insurance carriers (the “Customer” or “Carrier”) related to insurance plans produced through brokering, producing and servicing agreements between insurance carriers and members. The Company defines a “Member” as an individual, family or entity currently covered or seeking insurance coverage. The Company focuses primarily on agency services for insurance products in the “Healthcare” and property and casualty, which includes auto (collectively “P&C”) space, with nominal activity in the life insurance and bond sectors. Healthcare includes plans for individuals and families, Medicare supplements, ancillary and small businesses. The Company also earns revenue in the “Insurance Marketing” space as discussed further below. Consideration for all agency services typically is based on commissions calculated by applying contractual commission rates to policy premiums. For P&C, commission rates are applied to premiums due, whereas for healthcare, commission rates, including override commissions, are applied to monthly premiums received by the Carrier. The Company has two forms of billing practices, “Direct Bill” and “Agency Bill”. With Direct Bill, Carriers bill and collect policy premium payments directly from Members without any involvement from the Company. Commissions are paid to the Company by the Carrier in the following month. With Agency Bill, the Company bills Members premiums due and remits them to Carriers net of commission earned. The following outlines the core principles of ASC 606: Identification of the contract, or contracts, with a customer Identification of the performance obligations in the contract Determination of the transaction price Allocation of the transaction price to the performance obligations in the contract Recognition of revenue when, or as, the Company satisfies a performance obligation Healthcare revenue recognition: The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members. There typically is one performance obligation in contracts with Carriers, to perform agency services that culminate in monthly premium cash collections by the Carrier. The performance obligation is satisfied through a combination of agency services including, marketing carrier’s insurance plans, soliciting Member applications, binding, executing and servicing insurance policies on a continuous basis throughout a policy’s life cycle which includes and culminates with the Customer’s collection of monthly premiums. No commission is earned if cash is not received by Carrier. Thus, commission revenue is earned only after a month’s cash receipts from Members’ dues is received by the Customer. Each month’s Carrier cash collections is considered a separate unit sold and transferred to the Customer i.e., the satisfaction of that month’s performance obligation. Transaction price is typically stated in a contract and usually based on a commission rate applied to Member premiums paid and received by Carrier. The Company generally continues to receive commission payments from Carriers until a Member’s plan is cancelled or the Company terminates its agency agreement with the Carrier. Upon termination, the Company normally will no longer receive any commissions from Carriers even on business still in place. In some instances, trailing commissions could occur which would be recognized similar to other Healthcare revenue. With one performance obligation, allocation of transaction price is normally not necessary. Healthcare typically utilizes the Direct Bill method. The Company recognizes revenue at a point in time, when it satisfies its monthly performance obligation and control of the service transfers to the Customer. Transfer occurs when Member insurance premium cash payments are received by the Customer. The Customer’s receipt of cash is the culmination and complete satisfaction of the Company’s performance obligation, and the earnings process is complete. With Direct Bill, since the amount of monthly Customer cash receipts is unknown to the Company until the following month when notice is provided by Customer to Company, the Company accrues revenue at each period end. Any estimated revenue accrued and recognized at a period-end is trued up for financial reporting per actual revenue earned as provided by the Customer during the following month. P&C revenue recognition The Company identifies a contract when it has a binding agreement with a Carrier, the Customer, to provide agency services to Members. There typically is one performance obligation in contracts with Customers, to perform agency services to solicit, receive proposals and bind insurance policies culminating with policy placement. Commission revenue is earned at the time of policy placement. Transaction price is typically stated in a contract and usually based on commission rates applied to Member premiums due. With one performance obligation, allocation of transaction price is normally not necessary. P&C utilizes both the Agency Bill and Direct Bill methods, depending on the Carrier. The Company recognizes revenue at a point in time when it satisfies its performance obligation and control of the service transfers to the Customer. Transfer occurs when the policy placement process is complete. With both Direct Bill and Agency Bill, the Company accrues commission revenue in the period policies are placed. With Agency Bill, payment is typically received from Members in the month earned, however with Direct Bill, payment is typically received from Carriers in the month subsequent to the commissions being earned. Insurance Marketing revenue recognition: Medigap, a consolidated wholly owned subsidiary of the Company earns commission revenue by selling bound insurance policies with all renewal rights to insurance marketing organizations (the “IM Customer”). The IM Customers utilize innovative actuarial models to value and price policies purchased based on future projections. IM Customers pay a one-time commission per policy purchased to selling agencies based on a pre-agreed formula outlined in the parties’ contractual agreement. Commission payments are subject to chargeback in the event a policy is cancelled or lapses within 3 months of a policy’s effective date or until the first three payments are received from the insured party, depending on the IM Customer Contract. The Company identifies a contract when it has a binding agreement to sell issued insurance policies to the IM Customer. There is one performance obligation in IM Customer contracts, to sell the rights in Company procured issued insurance policies to the IM Customer. The performance obligation is satisfied when the rights to an issued policy have been transferred to the IM Customer. Transaction price is stated in a contract and is a set range of commission amounts based on each policy sold. There are two variable components to consideration received: a) Commissions are only earned once a policy is “Placed”, defined as, an active policy sold to the IM Customer where the IM Customer has received the initial insurance carrier payment with respect to such policy. The Company requires end-user insured parties to pay the initial premium to the insurance carrier upon issuance of a policy. Insurance carrier in turn pays IM Customer its initial payment soon thereafter. Thus, upon sale of an issued policy to IM Customer, the Company has provided a bound issued policy and ensured first premium payment has been completed by insured party. This results in virtual assurance that the IM Customer will receive its initial insurance carrier payment, and it is more than probable that a significant revenue reversal will not occur. The Company thus considers all policies sold to the IM Customer to be Placed for revenue recognition purposes. b) Commission revenue is subject to chargeback in full if a policy is cancelled or lapses within three months from the policy effective date or if the insured party does not make the first three payments of the policy. The Company uses historical activity as well as current factors to estimate the unconstrained variable consideration for recognition per the expected value method. A chargeback reserve liability is credited for the difference between cash consideration received and variable consideration recognized. At each reporting period, the Company remeasures the chargeback reserve liability and recognizes any change as an increase or decrease to the then current period revenue. As of March 31, 2022 and December 31, 2021, the chargeback reserve liability was $ 1,585,435 and $ 0 . With one performance obligation, allocation of transaction price is normally not necessary. The Company recognizes revenue at a point in time when it satisfies its performance obligation and control of an insurance policy transfers to the IM Customer. Transfer of control occurs when the Company submits the Policy to the IM Customer. IM Customers generally pay the Company weekly, and accruals are recorded as necessary at period end. Other revenue policies: When applicable, commission revenue is recognized net of any deductions for estimated commission adjustments due to lapses, policy cancellations, and revisions in coverage. The Company could earn additional revenue from contingent commissions, profit-sharing, override and bonuses based on meeting certain revenue or profit targets established periodically by the Carriers (collectively, “Contingent Commissions”). Contingent Commissions are earned when the Company achieves targets established by Carriers. The Carriers notify the Company when it has achieved the target. The Company recognizes revenue for any Contingent Commissions at the time it is reasonably assured that a significant revenue reversal is not probable, which is generally when a Carrier notifies the Company that it is on track or has earned a Contingent Commission. The following table disaggregates the Company’s revenue by line of business, showing commissions earned: SCHEDULE OF DISAGGREGATION REVENUE Three Months ended March 31, 2022 Medical/Life Property and Casualty Total Regular EBS $ 221,184 $ - $ 221,184 USBA 13,587 - 13,587 CCS/UIS - 43,881 43,881 Montana 506,721 - 506,721 Fortman 332,600 197,260 529,860 Altruis 1,304,872 - 1,304,872 Kush 438,591 - 438,591 Medigap 1,177,085 - 1,177,085 $ 3,994,640 $ 241,141 $ 4,235,781 Three Months ended March 31, 2021 Medical/Life Property and Casualty Contingent commission Total Regular EBS 208,994 - - 208,994 USBA 12,225 - - 12,225 CCS/UIS - 88,818 - 88,818 Montana 535,116 - - 535,116 Fortman 249,801 207,772 - 457,573 Altruis 1,021,004 - - 1,021,004 2,027,140 296,590 - 2,323,730 |
General and Administrative | General and Administrative General and administrative expenses primarily consist of personnel costs for the Company’s administrative functions, professional service fees, office rent, all employee travel expenses, and other general costs. |
Marketing and Advertising | Marketing and Advertising The Company’s direct channel expenses primarily consist of costs for e-mail marketing and newspaper advertisements. The Company’s online advertising channel expense primarily consist of social media ads. Advertising costs for both direct and online channels are expensed as incurred. |
Stock-Based Compensation | Stock-Based Compensation Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, based on the terms of the awards. The fair value of the stock-based payments to nonemployees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. As the Reliance Global Group, Inc. Equity Incentive Plan 2019 was adopted in January of 2019, the Company lacks the historical basis to estimate forfeitures and will recognize forfeitures as they occur. |
Leases | Leases The Company recognizes leases in accordance with Accounting Standards Codification Topic 842, “Leases” (“ASC 842” or “ASU 2016-12”). This standard provides enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases are recognized as a single lease expense, generally on a straight-line basis. The Company is the lessee in a contract when the Company obtains the right to use an asset. We currently lease real estate and office space under non-cancelable operating lease agreements. When applicable, consideration in a contract is allocated between lease and non-lease components. Lease payments are discounted using the implicit discount rate in the lease. If the implicit discount rate for the lease cannot be readily determined, the Company uses an estimate of its incremental borrowing rate. The Company did not have any contracts accounted for as finance leases as of March 31, 2021, or 2020. Operating leases are included in the line items right-of-use assets, current portion of leases payable, and leases payable, less current portion in the condensed consolidated balance sheets. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the condensed consolidated balance sheet and are expensed on a straight-line basis over the lease term in the condensed consolidated statement of operations. The Company determines a lease’s term by agreement with lessor and includes lease extension options and variable lease payments when option and/or variable payments are reasonably certain of being exercised or paid. |
Income Taxes | Income Taxes The Company recognizes deferred tax assets and liabilities using enacted tax rates for the effect of temporary differences between the book and tax basis of recorded assets and liabilities. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. In evaluating its ability to recover deferred tax assets within the jurisdiction in which they arise, the Company considers all available positive and negative evidence, including the expected reversals of taxable temporary differences, projected future taxable income, taxable income available via carryback to prior years, tax planning strategies, and results of recent operations. The Company assesses the realizability of its deferred tax assets, including scheduling the reversal of its deferred tax assets and liabilities, to determine the amount of valuation allowance needed. Scheduling the reversal of deferred tax asset and liability balances requires judgment and estimation. The Company believes the deferred tax liabilities relied upon as future taxable income in its assessment will reverse in the same period and jurisdiction and are of the same character as the temporary differences giving rise to the deferred tax assets that will be realized. |
Seasonality | Seasonality A greater number of the Company’s Medicare-related health insurance plans are sold in the fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage. The majority of the Company’s individual and family health insurance plans are sold in the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of these open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state. |
Prior Period Adjustments | Prior Period Adjustments During the June 30, 2021 quarterly financial reporting close process, the Company identified certain immaterial adjustments impacting the prior reporting period. Specifically, the Company identified adjustments to correct asset, liability and equity accounts in relation to historical purchase price allocation accounting, adjustments to true up accounts receivable and retained earnings for certain historical accrued revenues and true up the common stock issuable account. The Company has also separately reclassified its purchase software from property, plant and equipment to intangible assets which had no impact on the condensed consolidated statement of operations. The Company assessed the materiality of the adjustments to prior period financial statements in accordance with Securities and Exchange Commission Staff Accounting Bulletin No. (SAB) 99, Materiality Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements Accounting Changes and Error Corrections Accordingly, the Company’s comparative condensed consolidated financial statements and impacted notes have been revised from amounts previously reported to reflect these adjustments. The following table illustrates the impact on previously reported amounts and adjusted balances presented in the condensed consolidated financial statements for the period ended March 31, 2022. SUMMARIZES THE CHANGES TO THE PREVIOUSLY ISSUED FINANCIAL INFORMATION Account 3/31/2021 Adjustment 3/31/2021 Earn-out liability-Closing balance as of December 31, 2020 2,631,418 300,000 2,931,418 Goodwill-Closing balance as of December 31, 2020 9,265,070 (503,345 ) 8,761,725 Common stock issuable-Closing balance as of December 31, 2020 822,116 (482,116 ) 340,000 Additional paid-in-capital-Closing balance as of December 31, 2020 11,377,123 182,116 11,559,239 Accumulated Deficit-Closing balance as of December 31, 2020 (12,482,281 ) 122,601 (12,359,680 ) Common stock issuable 482,116 (482,116 ) - Accumulated Deficit (13,123,609 ) 150,003 (12,973,606 ) Additional paid-in-capital 25,810,147 182,116 25,992,263 Commission income 2,296,328 27,402 2,323,730 Total Revenue 2,296,328 27,402 2,323,730 Net Loss (641,328 ) 27,402 (613,926 ) EPS (0.09 ) (0.01 ) (0.08 ) |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (“ASU 2016-13”), which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financing Instruments—Credit Losses. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019. On November 15, 2019, the FASB delayed the effective date of FASB ASC Topic 326 for certain small public companies and other private companies. As amended, the effective date of ASC Topic 326 was delayed until fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition. The Company does not currently believe the adoption of this standard will have a significant impact on its financial statements, given its history of minimal bad debt expense relating to trade accounts receivable. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which eliminates certain exceptions to the general principles in Topic 740 and simplifies other areas of the existing guidance. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this pronouncement January 1, 2021 which did not have a material effect on the condensed consolidated financial statements. In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The ASU is effective for fiscal years beginning after December 15, 2021. The Company adopted ASU 2020-06 on January 1, 2022, which did not have a material impact on the condensed consolidated financial statements. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which amends ASC 805 to require an acquirer to, at the date of acquisition, recognize and measure contract assets and contract liabilities acquired in accordance with ASU 2014-9, Revenue from Contracts with Customers (Topic 606) as if the entity had originated the contracts. The guidance is effective for fiscal years beginning after December 15, 2022 with early adoption permitted. The Company elected to early adopt ASU 2021-08 as of January 1, 2022, which did not have a material impact on the condensed consolidated financial statements. |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
SCHEDULE OF PREVIOUSLY REPORTED CONSOLIDATED STATEMENTS OF OPERATIONS | SCHEDULE OF PREVIOUSLY REPORTED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2022 As Reported Adjustment As Corrected Basic earnings (loss) per share 1.95 0.51 2.46 Diluted earnings (loss) per share (6.30 ) (3.39 ) (9.69 ) Weighted average number of shares outstanding – Basic 1,215,016 (234,447 ) 980,569 Weighted average number of shares outstanding - Diluted 1,573,285 (377,805 ) 1,195,480 |
SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW | The reconciliation of cash and restricted cash reported within the applicable balance sheet accounts that sum to the total of cash and restricted cash presented in the statement of cash flows is as follows: SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW March 31, 2022 March 31, 2021 Cash $ 5,491,407 $ 9,432,070 Restricted cash 484,351 585,906 Total cash and restricted cash $ 5,975,758 $ 10,017,976 |
SCHEDULE OF PROPERTY AND EQUIPMENT | SCHEDULE OF PROPERTY AND EQUIPMENT Useful Life (in years) Computer equipment 5 Office equipment and furniture 7 Leasehold improvements Shorter of the useful life or the lease term |
SCHEDULE OF FAIR VALUE OF WARRANT COMMITMENT | SCHEDULE OF FAIR VALUE OF WARRANT COMMITMENT March 31, 2022 December 31, 2021 Stock price $ 4.31 $ 6.44 Volatility 90 % 90 % Time to expiry 5 5 Dividend yield 0 % 0 % Risk free rate 2.4 % 1.10 % Warrant liability, measurement input |
SCHEDULE OF RECONCILES WARRANT COMMITMENT | The following reconciles the fair values of the liability classified warrants: SCHEDULE OF RECONCILES WARRANT COMMITMENT Series B Warrant Commitment Series B warrant liabilities Placement agent warrants Total March 31, 2022 Series B Warrant Commitment Series B warrant liabilities Placement agent warrants Total Beginning balance $ 37,652,808 $ - $ - $ 37,652,808 Initial recognition - 55,061,119 1,525,923 56,587,042 Unrealized (gain) loss 17,408,311 (31,980,437 ) (946,461 ) (15,518,587 ) Warrants exercised or transferred (55,061,119 ) (55,061,119 ) Ending balance $ - $ 23,080,682 $ 579,462 $ 23,660,144 Series B Warrant Commitment Total December 31, 2021 Series B Warrant Commitment Total Beginning balance $ - $ - Initial recognition 20,244,497 20,244,497 Unrealized (gain) loss 17,408,311 17,408,311 Warrants exercised or transferred - - Ending balance $ 37,652,808 $ 37,652,808 |
SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE | SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE March 31, 2022 December 31, 2021 Beginning balance - January 1 $ 3,813,878 $ 2,931,418 Acquisitions and Settlements: - - JP Kush Acquisition - 1,694,166 CCS Write-off - (81,368 ) Altruis partial settlement - (452,236 ) - - Period adjustments: Fair value changes and accretion included in earnings * 407,071 (278,102 ) Ending balance $ 4,220,949 $ 3,813,878 * Recorded as a reduction to general and administrative expenses |
SCHEDULE OF FAIR VALUE MEASUREMENTS | Significant unobservable inputs used in the earn-out fair value measurements of the Company’s contingent consideration liabilities designated as Level 3 are as follows: SCHEDULE OF FAIR VALUE MEASUREMENTS March 31, 2022 December 31, 2021 Fair value $ 4,220,949 $ 3,813,878 Valuation technique Discounted cash flow Discounted cash flow Significant unobservable input Projected revenue and probability of achievement Projected revenue and probability of achievement |
SCHEDULE OF DISAGGREGATION REVENUE | The following table disaggregates the Company’s revenue by line of business, showing commissions earned: SCHEDULE OF DISAGGREGATION REVENUE Three Months ended March 31, 2022 Medical/Life Property and Casualty Total Regular EBS $ 221,184 $ - $ 221,184 USBA 13,587 - 13,587 CCS/UIS - 43,881 43,881 Montana 506,721 - 506,721 Fortman 332,600 197,260 529,860 Altruis 1,304,872 - 1,304,872 Kush 438,591 - 438,591 Medigap 1,177,085 - 1,177,085 $ 3,994,640 $ 241,141 $ 4,235,781 Three Months ended March 31, 2021 Medical/Life Property and Casualty Contingent commission Total Regular EBS 208,994 - - 208,994 USBA 12,225 - - 12,225 CCS/UIS - 88,818 - 88,818 Montana 535,116 - - 535,116 Fortman 249,801 207,772 - 457,573 Altruis 1,021,004 - - 1,021,004 2,027,140 296,590 - 2,323,730 |
SUMMARIZES THE CHANGES TO THE PREVIOUSLY ISSUED FINANCIAL INFORMATION | SUMMARIZES THE CHANGES TO THE PREVIOUSLY ISSUED FINANCIAL INFORMATION Account 3/31/2021 Adjustment 3/31/2021 Earn-out liability-Closing balance as of December 31, 2020 2,631,418 300,000 2,931,418 Goodwill-Closing balance as of December 31, 2020 9,265,070 (503,345 ) 8,761,725 Common stock issuable-Closing balance as of December 31, 2020 822,116 (482,116 ) 340,000 Additional paid-in-capital-Closing balance as of December 31, 2020 11,377,123 182,116 11,559,239 Accumulated Deficit-Closing balance as of December 31, 2020 (12,482,281 ) 122,601 (12,359,680 ) Common stock issuable 482,116 (482,116 ) - Accumulated Deficit (13,123,609 ) 150,003 (12,973,606 ) Additional paid-in-capital 25,810,147 182,116 25,992,263 Commission income 2,296,328 27,402 2,323,730 Total Revenue 2,296,328 27,402 2,323,730 Net Loss (641,328 ) 27,402 (613,926 ) EPS (0.09 ) (0.01 ) (0.08 ) |
STRATEGIC INVESTMENTS AND BUS_2
STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
JP Kush and Associates Inc [Member] | |
Business Acquisition [Line Items] | |
SCHEDULE OF ALLOCATION OF PURCHASE PRICE | The allocation of the purchase price in connection with the Kush Acquisition was calculated as follows: SCHEDULE OF ALLOCATION OF PURCHASE PRICE Description Fair Value Weighted Average Useful Life (Years) Accounts receivable $ 291,414 Trade name and trademarks 685,400 5 Customer relationships 551,000 10 Non-competition agreements 827,800 5 Goodwill 1,288,552 Indefinite Purchase consideration allocated $ 3,644,166 |
SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION | SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION March 31, 2021 Revenue $ 2,695,843 Net Income (Loss) $ (450,868 ) Earnings (Loss) per common share, basic $ (0.90 ) Earnings (Loss) per common share, diluted $ (0.90 ) |
Medigap Healthcare Insurance Company [Member] | |
Business Acquisition [Line Items] | |
SCHEDULE OF ALLOCATION OF PURCHASE PRICE | The preliminary allocation of the purchase price in connection with the acquisition of Medigap was calculated as follows: SCHEDULE OF ALLOCATION OF PURCHASE PRICE Description Fair Value Weighted Average Useful Life (Years) Property, plant and equipment $ 20,666 5 Right-of-use asset 317,787 Trade names 340,000 15 Customer relationships 4,550,000 12 Technology 67,000 3 Backlog 210,000 1 Chargeback reserve (1,484,473 ) Lease liability (317,787 ) Goodwill 19,199,008 Indefinite $ 22,902,201 |
SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION | SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION March 31, March 31, 2022 2021 Revenue $ 4,659,451 $ 3,602,106 Net Income (Loss) $ 9,355,584 $ (566,903 ) Earnings (Loss) per common share, basic $ 7.65 $ 1.2 ) Earnings (Loss) per common share, diluted $ 1.80 $ 1.2 ) |
PROPERTY AND EQUIPMENT (Tables)
PROPERTY AND EQUIPMENT (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Property, Plant and Equipment [Abstract] | |
SCHEDULE OF PROPERTY AND EQUIPMENTS | Property and equipment consists of the following: SCHEDULE OF PROPERTY AND EQUIPMENTS March 31, December 31, Computer equipment $ 79,379 $ 72,110 Office equipment and furniture 48,616 36,157 Leasehold Improvements 94,486 89,819 Property and equipment 222,481 198,086 Less: Accumulated depreciation (75,341 ) (67,727 ) Property and equipment, net $ 147,140 $ 130,359 |
GOODWILL AND OTHER INTANGIBLE_2
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
SCHEDULE OF IMPAIRMENT OF GOODWILL | SCHEDULE OF IMPAIRMENT OF GOODWILL Goodwill December 31, 2020 $ 8,761,725 Goodwill recognized in connection with Kush acquisition on May 1, 2021 $ 1,288,552 December 31, 2021 $ 10,050,277 Goodwill recognized in connection with Medigap acquisition on January 10, 2022 $ 19,199,008 March 31, 2022 $ 29,249,285 |
SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD | The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of March 31, 2022: SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD Weighted Average Remaining Amortization period (Years) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Trade name and trademarks 5.1 $ 2,117,475 $ (701,666 ) $ 1,415,809 Internally developed software 4.4 881,586 (67,682 ) 813,904 Customer relationships 9.7 8,787,290 (1,239,562 ) 7,547,728 Purchased software 0.3 562,327 (499,846 ) 62,481 Video Production Assets 0.8 50,000 (9,863 ) 40,137 Non-competition agreements 2.6 3,504,809 (1,653,617 ) 1,851,192 Contracts Backlog 0.8 210,000 (46,028 ) 163,972 $ 16,113,487 $ (4,218,264 ) $ 11,895,223 The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2021: Weighted Average Remaining Amortization period (Years) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Trade name and trademarks 3.5 $ 1,777,475 $ (609,822 ) $ 1,167,653 Internally developed software 4.7 595,351 (28,443 ) 566,908 Customer relationships 7.7 4,237,290 (1,048,726 ) 3,188,564 Purchased software 0.6 562,327 (452,985 ) 109,342 Video Production Assets 1.0 20,000 - 20,000 Non-competition agreements 2.9 3,504,809 (1,478,376 ) 2,026,433 $ 10,697,252 $ (3,618,352 ) $ 7,078,900 |
SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS | The following table reflects expected amortization expense as of March 31, 2022, for each of the following five years and thereafter: SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS Years ending December 31, Amortization Expense 2022 (remainder of year) $ 1,823,253 2023 2,064,243 2024 1,771,983 2025 1,325,184 2026 1,064,552 Thereafter 3,846,008 Total $ 11,895,223 |
ACCOUNTS PAYABLE AND ACCRUED _2
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Payables and Accruals [Abstract] | |
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES | Significant components of accounts payable and accrued liabilities were as follows: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES March 31, December 31, Accounts payable, $ 824,129 $ 547,117 Accrued expenses 116,619 2,170,215 Accrued credit card payables 75,459 36,103 Other accrued liabilities 26,910 5,725 Accounts payable and accrued liabilities $ 1,043,117 $ 2,759,160 |
LONG-TERM DEBT (Tables)
LONG-TERM DEBT (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Debt Disclosure [Abstract] | |
SCHEDULE OF LONG TERM DEBT | The composition of the long-term debt follows: SCHEDULE OF LONG TERM DEBT March 31, December 31, Oak Street Funding LLC Term Loan for the acquisition of EBS and USBA, net of deferred financing costs of $ 14,051 14,606 $ 470,249 $ 485,317 Oak Street Funding LLC Senior Secured Amortizing Credit Facility for the acquisition of CCS, net of deferred financing costs of $ 16,988 17,626 762,051 785,826 Oak Street Funding LLC Term Loan for the acquisition of SWMT, net of deferred financing costs of $ 10,556 11,027 859,892 884,720 Oak Street Funding LLC Term Loan for the acquisition of FIS, net of deferred financing costs of $ 41,206 42,660 2,164,855 2,226,628 Oak Street Funding LLC Term Loan for the acquisition of ABC, net of deferred financing costs of $ 46,989 48,609 3,521,493 3,616,754 7,778,540 7,999,245 Less: current portion (918,073 ) (913,920 ) Long-term debt $ 6,860,467 $ 7,085,325 |
SCHEDULE OF CUMULATIVE MATURITIES OF LONG-TERM OBLIGATIONS | SCHEDULE OF CUMULATIVE MATURITIES OF LONG-TERM OBLIGATIONS Fiscal year ending December 31, Maturities of 2022 (remainder of year) $ 682,348 2023 957,233 2024 1,010,835 2025 1,069,437 2026 1,130,416 Thereafter 3,058,062 Total 7,908,331 Less debt issuance costs (129,791 ) Total $ 7,778,540 |
SIGNIFICANT CUSTOMERS (Tables)
SIGNIFICANT CUSTOMERS (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Risks and Uncertainties [Abstract] | |
SCHEDULE OF CONCENTRATIONS OF REVENUES | Customers and IM Customers representing 10 % or more of total revenue are presented in the table below: SCHEDULE OF CONCENTRATIONS OF REVENUES For the three months ended Insurance Carrier 2022 2021 BlueCross BlueShield 10 % 22 % Priority Health 30 % 35 % LTC Global 25 % - % |
EQUITY (Tables)
EQUITY (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Equity [Abstract] | |
SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED | The following is a summary of the stock options granted, forfeited or expired, and exercised under the Plan for the three months ended March 31, 2022 and March 31, 2021 respectively: SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding at December 31, 2021 10,928 $ 232.50 2.61 $ - Granted - - - - Forfeited or expired - - - - Exercised - - - - Outstanding at March 31, 2022 10,928 $ 232.50 2.37 - Options Weighted Weighted Aggregate Outstanding at December 31, 2020 15,594 $ 231.45 3.63 $ - Granted - - - - Forfeited or expired - - - - Exercised - - - - Outstanding at March 31, 2021 15,594 $ 228.30 3.38 $ - |
SCHEDULE OF NON - VESTED STOCK OPTIONS | The following is a summary of the Company’s non-vested stock options as of March 31, 2022 and March 31, 2021 respectively: SCHEDULE OF NON - VESTED STOCK OPTIONS Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Non-vested at December 31, 2021 3,587 $ 227.10 0.90 Granted - - - Vested - - - Forfeited or expired - - - Non-vested at March 31, 2022 3,587 $ 227.10 0.82 Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Non-vested at December 31, 2020 10,636 $ 200.85 2.53 Granted - - - Vested - - - Forfeited or expired - - - Non-vested at March 31, 2021 10,636 $ 223.05 2.34 |
SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL | SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL Three Months Ended March 31, 2022 Three Months Ended March 31, 2021 Exercise price $ 0.16 0.26 $ 0.16 0.26 Expected term 3.25 3.75 3.25 3.75 Risk-free interest rate 0.38% 2.43 % 0.38% 2.43 % Estimated volatility 293.07% 517.13 % 293.07% 517.13 % Expected dividend - - Option price at valuation date $ 0.12 0.27 $ 0.12 0.31 |
EARNINGS (LOSS) PER SHARE (Tabl
EARNINGS (LOSS) PER SHARE (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Earnings Per Share [Abstract] | |
SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS | T he following calculates basic and diluted EPS: SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS Three Months Ended March 31, 2022 March 31, 2021 Net income (loss) $ 9,340,000 $ (613,926 ) Deemed dividend (6,930,335 ) - Net income (loss), numerator, basic computation 2,409,665 (613,926 ) Recognition and change in fair value of warrant liabilities (13,992,664 ) - Net income (loss), numerator, diluted computation $ (11,582,999 ) $ (613,926 ) Weighted average shares - denominator basic computation 980,569 502,825 Effect of Series B warrant liabilities 214,911 - Weighted average shares, as adjusted - denominator diluted computation 1,195,480 502,825 Earnings (loss) per common share - basic $ 2.46 $ (1.22 ) Earnings (loss) per common share - diluted $ (9.69 ) $ (1.22 ) |
SCHEDULE OF ANTI-DILUTIVE SECURITIES IN WEIGHTED AVERAGE SHARES | Additionally, the following are considered anti-dilutive securities excluded from weighted-average shares used to calculate diluted net loss per common share: SCHEDULE OF ANTI-DILUTIVE SECURITIES IN WEIGHTED AVERAGE SHARES For the Three Months Ended March 31, 2022 March 31, 2021 Shares subject to outstanding common stock options 10,928 10,928 Shares subject to outstanding Series A warrants 113,000 138,000 Shares subject to unvested stock awards 661 1,200 Shares subject to conversion of Series B preferred stock 147,939 - Weighted-average anti-dilutive securities 147,939 - |
LEASES (Tables)
LEASES (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Leases | |
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT | Future minimum lease payment under these operating leases consisted of the following: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT Year ending December 31, Operating Lease 2022 $ 371,025 2023 439,110 2024 172,690 2025 112,923 2026 113,736 Thereafter 268,197 Total undiscounted operating lease payments 1,477,681 Less: Imputed interest 172,402 Present value of operating lease liabilities $ 1,305,279 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
SCHEDULE OF EARN-OUT LIABILITY | The following outlines changes to the Company’s earn-out liability balances inclusive of accumulated accretion for the respective period ended March 31, 2022 and December 31, 2021: SCHEDULE OF EARN-OUT LIABILITY CCS Fortman Montana Altruis Kush Total Ending balance December 31, 2021 $ - $ 515,308 $ 615,969 $ 992,868 $ 1,689,733 $ 3,813,878 Changes due to fair value adjustments - 29,522 37,741 - 339,808 407,071 Changes due to business combinations Changes due to payments Changes due to write-offs Ending balance March 31, 2022 $ - $ 544,830 $ 653,710 $ 992,868 $ 2,029,541 $ 4,220,949 CCS Fortman Montana Altruis Kush Total Ending balance December 31, 2020 $ 81,368 $ 432,655 $ 522,553 $ 1,894,842 $ - $ 2,931,418 Changes due to business combinations - - - - 1,694,166 1,694,166 Changes due to payments - - - (452,236 ) - (452,236 ) Changes due to fair value adjustments - 82,653 93,416 (449,738 ) (4,433 ) (278,102 ) Changes due to write-offs (81,368 ) - - - - (81,368 ) Ending balance December 31, 2021 $ - $ 515,308 $ 615,969 $ 992,868 $ 1,689,733 $ 3,813,878 |
SCHEDULE OF PREVIOUSLY REPORTED
SCHEDULE OF PREVIOUSLY REPORTED CONSOLIDATED STATEMENTS OF OPERATIONS (Details) - $ / shares | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Basic earnings (loss) per share | $ 2.46 | $ (1.22) |
Diluted earnings (loss) per share | $ (9.69) | $ (1.22) |
Weighted average number of shares outstanding – Basic | 980,569 | 502,825 |
Weighted average number of shares outstanding - Diluted | 1,195,480 | 502,825 |
Previously Reported [Member] | ||
Basic earnings (loss) per share | $ 1.95 | |
Diluted earnings (loss) per share | $ (6.30) | |
Weighted average number of shares outstanding – Basic | 1,215,016 | |
Weighted average number of shares outstanding - Diluted | 1,573,285 | |
Revision of Prior Period, Adjustment [Member] | ||
Basic earnings (loss) per share | $ 0.51 | |
Diluted earnings (loss) per share | $ (3.39) | |
Weighted average number of shares outstanding – Basic | (234,447) | |
Weighted average number of shares outstanding - Diluted | (377,805) |
SCHEDULE OF RESTRICTED CASH IN
SCHEDULE OF RESTRICTED CASH IN STATEMENT OF CASH FLOW (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 | Mar. 31, 2021 |
Accounting Policies [Abstract] | |||
Cash | $ 5,491,407 | $ 4,136,180 | $ 9,432,070 |
Restricted cash | 484,351 | $ 484,542 | 585,906 |
Total cash and restricted cash | $ 5,975,758 | $ 10,017,976 |
SCHEDULE OF PROPERTY AND EQUIPM
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) | 3 Months Ended |
Mar. 31, 2022 | |
Computer Equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful life | 5 years |
Office Equipment and Furniture [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful life | 7 years |
Leasehold Improvements [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful life description | Shorter of the useful life or the lease term |
SCHEDULE OF FAIR VALUE OF WARRA
SCHEDULE OF FAIR VALUE OF WARRANT COMMITMENT (Details) | Mar. 31, 2022 | Dec. 31, 2021 |
Measurement Input, Share Price [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrant liability, measurement input | 4.31 | 6.44 |
Measurement Input, Price Volatility [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrant liability, measurement input | 90 | 90 |
Measurement Input, Expected Term [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrants and Rights Outstanding, Term | 5 years | 5 years |
Measurement Input, Expected Dividend Rate [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrant liability, measurement input | 0 | 0 |
Measurement Input, Risk Free Interest Rate [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Warrant liability, measurement input | 2.4 | 1.10 |
SCHEDULE OF RECONCILES WARRANT
SCHEDULE OF RECONCILES WARRANT COMMITMENT (Details) - USD ($) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
Offsetting Assets [Line Items] | ||
Beginning balance | $ 37,652,808 | |
Initial recognition | 56,587,042 | 20,244,497 |
Unrealized (gain) loss | (15,518,587) | 17,408,311 |
Warrants exercised or transferred | (55,061,119) | |
Ending balance | 23,660,144 | 37,652,808 |
Series B Warrant Commitment [Member] | ||
Offsetting Assets [Line Items] | ||
Beginning balance | 37,652,808 | |
Initial recognition | 20,244,497 | |
Unrealized (gain) loss | 17,408,311 | 17,408,311 |
Warrants exercised or transferred | (55,061,119) | |
Ending balance | 37,652,808 | |
Series B Warrant Liability [Member] | ||
Offsetting Assets [Line Items] | ||
Beginning balance | ||
Initial recognition | 55,061,119 | |
Unrealized (gain) loss | (31,980,437) | |
Ending balance | 23,080,682 | |
Placement Agent Warrants [Member] | ||
Offsetting Assets [Line Items] | ||
Beginning balance | ||
Initial recognition | 1,525,923 | |
Unrealized (gain) loss | (946,461) | |
Ending balance | $ 579,462 |
SCHEDULE OF GAIN OR LOSSES RECO
SCHEDULE OF GAIN OR LOSSES RECOGNIZED FAIR VALUE (Details) - USD ($) | 3 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | ||
Defined Benefit Plan Disclosure [Line Items] | |||
Beginning balance - January 1 | $ 3,813,878 | $ 2,931,418 | |
Ending balance | 4,220,949 | ||
Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Beginning balance - January 1 | 3,813,878 | 2,931,418 | |
Altruis partial settlement | |||
Fair value changes and accretion included in earnings | [1] | 407,071 | (278,102) |
Ending balance | 4,220,949 | 3,813,878 | |
Fair Value, Inputs, Level 3 [Member] | JP Kush Acquisition [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Altruis partial settlement | 1,694,166 | ||
Fair Value, Inputs, Level 3 [Member] | CCS Write-off [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Altruis partial settlement | (81,368) | ||
Fair Value, Inputs, Level 3 [Member] | Altruis Partial Settlement [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Altruis partial settlement | $ (452,236) | ||
[1]Recorded as a reduction to general and administrative expenses |
SCHEDULE OF FAIR VALUE MEASUREM
SCHEDULE OF FAIR VALUE MEASUREMENTS (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value | $ 446,538 | $ 516,023 | $ 2,631,418 |
Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value | $ 4,220,949 | $ 3,813,878 | |
Valuation technique | Discounted cash flow | Discounted cash flow | |
Significant unobservable input | Projected revenue and probability of achievement | Projected revenue and probability of achievement |
SCHEDULE OF DISAGGREGATION REVE
SCHEDULE OF DISAGGREGATION REVENUE (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | $ 4,235,781 | $ 2,323,730 |
Employee Benefits, Solutions, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 221,184 | 208,994 |
US Benefits Alliance, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 13,587 | 12,225 |
Commercial Coverage Solutions LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 43,881 | 88,818 |
Southwestern Montana Financial Center, Inc. [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 506,721 | 535,116 |
Fortman Insurance Services, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 529,860 | 457,573 |
Altruis Benefits Consulting, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 1,304,872 | 1,021,004 |
Kush [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 438,591 | |
Medigap [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 1,177,085 | |
Medical/Life [Member] | Regular [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 3,994,640 | 2,027,140 |
Medical/Life [Member] | Regular [Member] | Employee Benefits, Solutions, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 221,184 | 208,994 |
Medical/Life [Member] | Regular [Member] | US Benefits Alliance, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 13,587 | 12,225 |
Medical/Life [Member] | Regular [Member] | Commercial Coverage Solutions LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | ||
Medical/Life [Member] | Regular [Member] | Southwestern Montana Financial Center, Inc. [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 506,721 | 535,116 |
Medical/Life [Member] | Regular [Member] | Fortman Insurance Services, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 332,600 | 249,801 |
Medical/Life [Member] | Regular [Member] | Altruis Benefits Consulting, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 1,304,872 | 1,021,004 |
Medical/Life [Member] | Regular [Member] | Kush [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 438,591 | |
Medical/Life [Member] | Regular [Member] | Medigap [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 1,177,085 | |
Property and Casualty [Member] | Regular [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 241,141 | 296,590 |
Property and Casualty [Member] | Regular [Member] | Employee Benefits, Solutions, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | ||
Property and Casualty [Member] | Regular [Member] | US Benefits Alliance, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | ||
Property and Casualty [Member] | Regular [Member] | Commercial Coverage Solutions LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 43,881 | 88,818 |
Property and Casualty [Member] | Regular [Member] | Southwestern Montana Financial Center, Inc. [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | ||
Property and Casualty [Member] | Regular [Member] | Fortman Insurance Services, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | 197,260 | 207,772 |
Property and Casualty [Member] | Regular [Member] | Altruis Benefits Consulting, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | ||
Property and Casualty [Member] | Regular [Member] | Kush [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | ||
Property and Casualty [Member] | Regular [Member] | Medigap [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | ||
Contingent commission [Member] | Regular [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | ||
Contingent commission [Member] | Regular [Member] | Employee Benefits, Solutions, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | ||
Contingent commission [Member] | Regular [Member] | US Benefits Alliance, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | ||
Contingent commission [Member] | Regular [Member] | Commercial Coverage Solutions LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | ||
Contingent commission [Member] | Regular [Member] | Southwestern Montana Financial Center, Inc. [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | ||
Contingent commission [Member] | Regular [Member] | Fortman Insurance Services, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax | ||
Contingent commission [Member] | Regular [Member] | Altruis Benefits Consulting, LLC [Member] | ||
Product Information [Line Items] | ||
Revenue from contract with customer, excluding assessed tax |
SUMMARIZES THE CHANGES TO THE P
SUMMARIZES THE CHANGES TO THE PREVIOUSLY ISSUED FINANCIAL INFORMATION (Details) - USD ($) | 3 Months Ended | |||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Earn-out liability-Closing balance as of December 31, 2020 | $ 1,173,383 | $ 1,024,831 | $ 2,931,418 | |
Goodwill-Closing balance as of December 31, 2020 | 29,249,285 | 10,050,277 | 8,761,725 | |
Common stock issuable | 340,000 | |||
Additional paid-in-capital | 35,304,698 | 25,992,263 | 27,329,201 | 11,559,239 |
Accumulated Deficit | (24,118,145) | (12,973,606) | $ (33,458,145) | (12,359,680) |
Commission income | 4,235,781 | 2,323,730 | ||
Total Revenue | 4,235,781 | 2,323,730 | ||
Net Loss | $ 9,340,000 | $ (613,926) | ||
EPS | $ (0.08) | |||
Previously Reported [Member] | ||||
Earn-out liability-Closing balance as of December 31, 2020 | 2,631,418 | |||
Goodwill-Closing balance as of December 31, 2020 | 9,265,070 | |||
Common stock issuable | $ 482,116 | 822,116 | ||
Additional paid-in-capital | 25,810,147 | 11,377,123 | ||
Accumulated Deficit | (13,123,609) | (12,482,281) | ||
Commission income | 2,296,328 | |||
Total Revenue | 2,296,328 | |||
Net Loss | $ (641,328) | |||
EPS | $ (0.09) | |||
Revision of Prior Period, Adjustment [Member] | ||||
Earn-out liability-Closing balance as of December 31, 2020 | 300,000 | |||
Goodwill-Closing balance as of December 31, 2020 | (503,345) | |||
Common stock issuable | $ (482,116) | (482,116) | ||
Additional paid-in-capital | 182,116 | 182,116 | ||
Accumulated Deficit | 150,003 | $ 122,601 | ||
Commission income | 27,402 | |||
Total Revenue | 27,402 | |||
Net Loss | $ 27,402 | |||
EPS | $ (0.01) |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | 3 Months Ended | |||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Property, Plant and Equipment [Line Items] | ||||
Increase to basic earnings per share | $ 2.46 | $ (1.22) | ||
Increase to diluted loss per share | $ 9.69 | $ 1.22 | ||
Decrease to weighted average number of shares outstanding - basic | (980,569) | (502,825) | ||
Decrease to weighted average number of shares outstanding - diluted | (1,195,480) | (502,825) | ||
Cash and restricted cash | $ 5,976,000 | |||
Current asset | 7,269,758 | $ 7,981,501 | ||
Current liabilities | 7,835,114 | 44,981,252 | ||
Working capital deficit | 565,000 | |||
Stockholders' equity | 11,252,333 | $ 13,957,299 | (26,066,129) | $ (63,012) |
Operating loss | 2,398,167 | 484,855 | ||
Recognition and change in fair value of warrant liabilities | 11,845,964 | |||
Net income | 9,340,000 | (613,926) | ||
Cash flows from operations activites | 343,280 | 646,602 | ||
Additional paid-in capital | 35,304,698 | 25,992,263 | 27,329,201 | 11,559,239 |
Earn-out liability, current portion | 3,774,411 | 3,297,855 | ||
Current portion of the earn-out liability | 3,774,411 | 3,297,855 | ||
Non-current portion of the earn-out liability | 446,538 | 516,023 | ||
Undiscounted remaining earn out payments | 4,345,000 | |||
Unamortized deferred financing costs | 129,791 | 134,528 | ||
Reserve liability | $ 1,585,435 | 0 | ||
Minimum [Member] | ||||
Property, Plant and Equipment [Line Items] | ||||
Estimated useful lives of intangible assets | 3 years | |||
Maximum [Member] | ||||
Property, Plant and Equipment [Line Items] | ||||
Estimated useful lives of intangible assets | 20 years | |||
Fair Value, Inputs, Level 3 [Member] | ||||
Property, Plant and Equipment [Line Items] | ||||
Earn-out liability, current portion | $ 4,220,949 | $ 3,813,878 | ||
Purchase Agreement [Member] | ||||
Property, Plant and Equipment [Line Items] | ||||
Additional paid-in capital | $ 17,853,352 | |||
Revision of Prior Period, Adjustment [Member] | ||||
Property, Plant and Equipment [Line Items] | ||||
Increase to basic earnings per share | $ 0.51 | |||
Increase to diluted loss per share | $ 3.39 | |||
Decrease to weighted average number of shares outstanding - basic | 234,447 | |||
Decrease to weighted average number of shares outstanding - diluted | 377,805 | |||
Net income | 27,402 | |||
Additional paid-in capital | $ 182,116 | $ 182,116 |
SCHEDULE OF ALLOCATION OF PURCH
SCHEDULE OF ALLOCATION OF PURCHASE PRICE (Details) - USD ($) | 3 Months Ended | 12 Months Ended | ||
May 01, 2021 | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Business Acquisition [Line Items] | ||||
Goodwill | $ 29,249,285 | $ 10,050,277 | $ 8,761,725 | |
Customer Relationships [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average useful life years | 9 years 8 months 12 days | 7 years 8 months 12 days | ||
Non-competition Agreements [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average useful life years | 2 years 7 months 6 days | 2 years 10 months 24 days | ||
JP Kush and Associates Inc [Member] | ||||
Business Acquisition [Line Items] | ||||
Accounts receivable | $ 291,414 | |||
Trade name and trademarks | 685,400 | |||
Customer relationships | 551,000 | |||
Non-competition agreements | 827,800 | |||
Goodwill | $ 1,288,552 | |||
Purchase consideration allocated | $ 3,644,166 | |||
JP Kush and Associates Inc [Member] | Trade Name And Trademarks [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average useful life years | 5 years | |||
JP Kush and Associates Inc [Member] | Customer Relationships [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average useful life years | 10 years | |||
JP Kush and Associates Inc [Member] | Non-competition Agreements [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average useful life years | 5 years | |||
JP Kush and Associates Inc [Member] | Goodwill [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average useful life description | Indefinite | |||
Medigap Healthcare Insurance Company [Member] | ||||
Business Acquisition [Line Items] | ||||
Goodwill | 19,199,008 | |||
Purchase consideration allocated | $ 22,902,201 | |||
Medigap Healthcare Insurance Company [Member] | Customer Relationships [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average useful life years | 12 years | |||
Purchase consideration allocated | $ 4,550,000 | |||
Medigap Healthcare Insurance Company [Member] | Goodwill [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average useful life description | Indefinite | |||
Purchase consideration allocated | $ 19,199,008 | |||
Medigap Healthcare Insurance Company [Member] | Property, Plant and Equipment [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average useful life years | 5 years | |||
Purchase consideration allocated | $ 20,666 | |||
Medigap Healthcare Insurance Company [Member] | Right of use asset [Member] | ||||
Business Acquisition [Line Items] | ||||
Purchase consideration allocated | $ 317,787 | |||
Medigap Healthcare Insurance Company [Member] | Trade Names [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average useful life years | 15 years | |||
Purchase consideration allocated | $ 340,000 | |||
Medigap Healthcare Insurance Company [Member] | Technology-Based Intangible Assets [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average useful life years | 3 years | |||
Purchase consideration allocated | $ 67,000 | |||
Medigap Healthcare Insurance Company [Member] | Back log [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average useful life years | 1 year | |||
Purchase consideration allocated | $ 210,000 | |||
Medigap Healthcare Insurance Company [Member] | Chargeback reserve [Member] | ||||
Business Acquisition [Line Items] | ||||
Purchase consideration allocated | (1,484,473) | |||
Medigap Healthcare Insurance Company [Member] | Lease liability [Member] | ||||
Business Acquisition [Line Items] | ||||
Purchase consideration allocated | $ (317,787) |
SCHEDULE OF PRO FORMA INFORMATI
SCHEDULE OF PRO FORMA INFORMATION RELATED TO ACQUISITION (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
JP Kush and Associates Inc [Member] | ||
Business Acquisition [Line Items] | ||
Revenue | $ 2,695,843 | |
Net Income (Loss) | $ (450,868) | |
Earnings (Loss) per common share, basic | $ (0.90) | |
Earnings (Loss) per common share, diluted | $ (0.90) | |
Medigap Healthcare Insurance Company [Member] | ||
Business Acquisition [Line Items] | ||
Revenue | $ 4,659,451 | $ 3,602,106 |
Net Income (Loss) | $ 9,355,584 | $ (566,903) |
Earnings (Loss) per common share, basic | $ 7.65 | $ 1.2 |
Earnings (Loss) per common share, diluted | $ 1.80 | $ 1.2 |
STRATEGIC INVESTMENTS AND BUS_3
STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS (Details Narrative) | 1 Months Ended | 3 Months Ended | 4 Months Ended | 12 Months Ended | |||
Jan. 10, 2022 USD ($) shares | May 01, 2021 USD ($) | May 31, 2021 shares | Mar. 31, 2022 USD ($) | Apr. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | |
Business Acquisition [Line Items] | |||||||
Stock Issued During Period, Value, Acquisitions | $ 4,763,451 | ||||||
Goodwill | $ 29,249,285 | $ 10,050,277 | $ 8,761,725 | ||||
Measurement Input Royalty Rate [Member] | Trade Names [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Business combination, measurement input | 0.5 | ||||||
Measurement Input, Discount Rate [Member] | Trade Names [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Business combination, measurement input | 11 | ||||||
Measurement Input, Discount Rate [Member] | Customer Relationships [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Business combination, measurement input | 11 | ||||||
Measurement Input, Discount Rate [Member] | Back log [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Business combination, measurement input | 11 | ||||||
Measurement Input Obsolescence Rate [Member] | Technology-Based Intangible Assets [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Business combination, measurement input | 40.3 | ||||||
JP Kush and Associates Inc [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Business Combination, Bargain Purchase, Gain Recognized, Amount | $ 3,644,166 | ||||||
Payments to Acquire Businesses, Gross | 1,900,000 | ||||||
Stock Issued During Period, Value, Acquisitions | 50,000 | ||||||
Goodwill | 1,288,552 | ||||||
Acquisition costs | $ 58,092 | ||||||
Revenue from acquired entity | $ 500,000 | ||||||
Shares issued upon termination of employee | $ 219,097 | ||||||
Stock Issued During Period, Shares, Acquisitions | shares | 995 | ||||||
Medigap Healthcare Insurance Company [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Business Combination, Bargain Purchase, Gain Recognized, Amount | $ 20,096,250 | ||||||
Payments to Acquire Businesses, Gross | $ 18,138,750 | ||||||
Goodwill | $ 19,199,008 | ||||||
Acquisition costs | $ 94,065 | ||||||
Revenue from acquired entity | 1,177,000 | ||||||
Shares issued upon termination of employee | $ 148,000 | ||||||
Stock Issued During Period, Shares, Acquisitions | shares | 40,402 |
INVESTMENT IN NSURE, INC. (Deta
INVESTMENT IN NSURE, INC. (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | |||||||
Aug. 20, 2020 | Aug. 05, 2020 | Jun. 01, 2020 | Feb. 19, 2020 | Feb. 10, 2020 | Feb. 28, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | |
Investments | $ 1,350,000 | $ 1,350,000 | |||||||
Number of shares issued | 138,000 | ||||||||
Proceeds from issuance of common stock | $ 12,420,000 | $ 10,481,938 | |||||||
NSURE, Inc. [Member] | Third-Party Individual [Member] | |||||||||
Number of shares issued | 3,111 | ||||||||
Proceeds from issuance of common stock | $ 1,000,000 | ||||||||
Securities Purchase Agreement [Member] | Common Class A [Member] | NSURE, Inc. [Member] | |||||||||
Ownership interest | 35% | ||||||||
Securities Purchase Agreement [Member] | NSURE, Inc. [Member] | Share-Based Payment Arrangement, Tranche One [Member] | |||||||||
Investments | $ 1,000,000 | ||||||||
Number of shares issued | 291,873 | ||||||||
Securities Purchase Agreement [Member] | NSURE, Inc. [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | |||||||||
Investments | $ 3,000,000 | ||||||||
Securities Purchase Agreement [Member] | NSURE, Inc. [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | |||||||||
Investments | 16,000,000 | ||||||||
Securities Purchase Agreement [Member] | NSURE, Inc. [Member] | Common Class A [Member] | |||||||||
Investments | $ 50,000 | $ 100,000 | $ 200,000 | $ 1,350,000 | |||||
Number of shares issued | 43,781 | 43,781 | 58,375 | 5,837,462 | |||||
Securities Purchase Agreement [Member] | NSURE, Inc. [Member] | Maximum [Member] | |||||||||
Investments | $ 20,000,000 |
SCHEDULE OF PROPERTY AND EQUI_2
SCHEDULE OF PROPERTY AND EQUIPMENTS (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Property, Plant and Equipment [Line Items] | ||
Property and equipment | $ 222,481 | $ 198,086 |
Less: Accumulated depreciation | (75,341) | (67,727) |
Property and equipment, net | 147,140 | 130,359 |
Computer Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | 79,379 | 72,110 |
Office Equipment and Furniture [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | 48,616 | 36,157 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | $ 94,486 | $ 89,819 |
PROPERTY AND EQUIPMENT (Details
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Property, Plant and Equipment [Abstract] | ||
Depreciation expense | $ 7,614 | $ 2,658 |
SCHEDULE OF IMPAIRMENT OF GOODW
SCHEDULE OF IMPAIRMENT OF GOODWILL (Details) - USD ($) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Goodwill, beginning balance | $ 10,050,277 | $ 8,761,725 |
Goodwill recognized in connection with acquisition | 19,199,008 | 1,288,552 |
Goodwill, ending balance | $ 29,249,285 | $ 10,050,277 |
SCHEDULE OF INTANGIBLE ASSETS A
SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD (Details) - USD ($) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
Finite-Lived Intangible Assets [Line Items] | ||
Gross carrying amount | $ 16,113,487 | $ 10,697,252 |
Accumulated amortization | (4,218,264) | (3,618,352) |
Net carrying amount | $ 11,895,223 | $ 7,078,900 |
Trademarks and Trade Names [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted average remaining amortization period | 5 years 1 month 6 days | 3 years 6 months |
Gross carrying amount | $ 2,117,475 | $ 1,777,475 |
Accumulated amortization | (701,666) | (609,822) |
Net carrying amount | $ 1,415,809 | $ 1,167,653 |
Internally Developed Software [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted average remaining amortization period | 4 years 4 months 24 days | 4 years 8 months 12 days |
Gross carrying amount | $ 881,586 | $ 595,351 |
Accumulated amortization | (67,682) | (28,443) |
Net carrying amount | $ 813,904 | $ 566,908 |
Customer Relationships [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted average remaining amortization period | 9 years 8 months 12 days | 7 years 8 months 12 days |
Gross carrying amount | $ 8,787,290 | $ 4,237,290 |
Accumulated amortization | (1,239,562) | (1,048,726) |
Net carrying amount | $ 7,547,728 | $ 3,188,564 |
Purchased Software [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted average remaining amortization period | 3 months 18 days | 7 months 6 days |
Gross carrying amount | $ 562,327 | $ 562,327 |
Accumulated amortization | (499,846) | (452,985) |
Net carrying amount | $ 62,481 | $ 109,342 |
Video Production Assets [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted average remaining amortization period | 9 months 18 days | 1 year |
Gross carrying amount | $ 50,000 | $ 20,000 |
Accumulated amortization | (9,863) | |
Net carrying amount | $ 40,137 | $ 20,000 |
Non-competition Agreements [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted average remaining amortization period | 2 years 7 months 6 days | 2 years 10 months 24 days |
Gross carrying amount | $ 3,504,809 | $ 3,504,809 |
Accumulated amortization | (1,653,617) | (1,478,376) |
Net carrying amount | $ 1,851,192 | $ 2,026,433 |
Contracts backlog [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted average remaining amortization period | 9 months 18 days | |
Gross carrying amount | $ 210,000 | |
Accumulated amortization | (46,028) | |
Net carrying amount | $ 163,972 |
SCHEDULE OF AMORTIZATION EXPENS
SCHEDULE OF AMORTIZATION EXPENSE OF ACQUIRED INTANGIBLES ASSETS (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
2022 (remainder of year) | $ 1,823,253 | |
2023 | 2,064,243 | |
2024 | 1,771,983 | |
2025 | 1,325,184 | |
2026 | 1,064,552 | |
Thereafter | 3,846,008 | |
Total | $ 11,895,223 | $ 7,078,900 |
GOODWILL AND OTHER INTANGIBLE_3
GOODWILL AND OTHER INTANGIBLE ASSETS (Details Narrative) - USD ($) | 3 Months Ended | |||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Goodwill | $ 29,249,285 | $ 10,050,277 | $ 8,761,725 | |
Amortization of intangible assets | $ 599,911 | $ 283,569 | ||
Revision of Prior Period, Adjustment [Member] | ||||
Goodwill | (503,345) | |||
Previously Reported [Member] | ||||
Goodwill | $ 9,265,070 |
SCHEDULE OF ACCOUNTS PAYABLE AN
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Payables and Accruals [Abstract] | ||
Accounts payable, | $ 824,129 | $ 547,117 |
Accrued expenses | 116,619 | 2,170,215 |
Accrued credit card payables | 75,459 | 36,103 |
Other accrued liabilities | 26,910 | 5,725 |
Accounts payable and accrued liabilities | $ 1,043,117 | $ 2,759,160 |
SCHEDULE OF LONG TERM DEBT (Det
SCHEDULE OF LONG TERM DEBT (Details) (Parenthetical) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
CCS [Member] | ||
Line of Credit Facility [Line Items] | ||
Net of deferred financing cost | $ 16,988 | $ 17,626 |
EBS and USBA [Member] | ||
Line of Credit Facility [Line Items] | ||
Net of deferred financing cost | 14,051 | 14,606 |
SWMT [Member] | ||
Line of Credit Facility [Line Items] | ||
Net of deferred financing cost | 10,556 | 11,027 |
FIS [Member] | ||
Line of Credit Facility [Line Items] | ||
Net of deferred financing cost | 41,206 | 42,660 |
ABC [Member] | ||
Line of Credit Facility [Line Items] | ||
Net of deferred financing cost | $ 46,989 | $ 48,609 |
SCHEDULE OF LONG TERM DEBT (D_2
SCHEDULE OF LONG TERM DEBT (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Line of Credit Facility [Line Items] | ||
Long term debt | $ 7,778,540 | $ 7,999,245 |
Current portion of long-term debt | (918,073) | (913,920) |
Long term debt, excluding current maturities | 6,860,467 | 7,085,325 |
CCS [Member] | ||
Line of Credit Facility [Line Items] | ||
Long term debt | 762,051 | 785,826 |
EBS and USBA [Member] | ||
Line of Credit Facility [Line Items] | ||
Long term debt | 470,249 | 485,317 |
SWMT [Member] | ||
Line of Credit Facility [Line Items] | ||
Long term debt | 859,892 | 884,720 |
FIS [Member] | ||
Line of Credit Facility [Line Items] | ||
Long term debt | 2,164,855 | 2,226,628 |
ABC [Member] | ||
Line of Credit Facility [Line Items] | ||
Long term debt | $ 3,521,493 | $ 3,616,754 |
SCHEDULE OF CUMULATIVE MATURITI
SCHEDULE OF CUMULATIVE MATURITIES OF LONG-TERM OBLIGATIONS (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Debt Disclosure [Abstract] | ||
2022 (remainder of year) | $ 682,348 | |
2023 | 957,233 | |
2024 | 1,010,835 | |
2025 | 1,069,437 | |
2026 | 1,130,416 | |
Thereafter | 3,058,062 | |
Total | 7,908,331 | |
Less debt issuance costs | (129,791) | |
Total | $ 7,778,540 | $ 7,999,245 |
LONG-TERM DEBT (Details Narrati
LONG-TERM DEBT (Details Narrative) - USD ($) | 12 Months Ended | ||||
Dec. 07, 2018 | Aug. 01, 2018 | Dec. 31, 2019 | Mar. 31, 2022 | Dec. 31, 2018 | |
Short-Term Debt [Line Items] | |||||
Debt issuance costs | $ 129,791 | ||||
Employee Benefits, Solutions, LLC, and US Benefits Alliance [Member] | Credit Agreement [Member] | Oak Street Funding LLC [Member] | |||||
Short-Term Debt [Line Items] | |||||
Borrowings | $ 750,000 | ||||
Debt description | Interest accrues at 5.00% on the basis of a 360-day year, maturing 120 months from the Amortization Date (September 25, 2018) | ||||
Debt instrument, interest rate | 5% | ||||
Debt issuance costs | $ 22,188 | ||||
Commercial Coverage Solutions LLC [Member] | Oak Street Funding LLC [Member] | Senior Secured Amortizing Credit Facility [Member] | |||||
Short-Term Debt [Line Items] | |||||
Borrowings | $ 1,025,000 | ||||
Debt description | The borrowing rate under the Facility is a variable rate equal to Prime +1.50% and matures 10 years from the closing date | ||||
Debt issuance costs | $ 25,506 | ||||
Debt instrument term | 10 years | ||||
Commercial Coverage Solutions LLC [Member] | Oak Street Funding LLC [Member] | Senior Secured Amortizing Credit Facility [Member] | Prime Rate [Member] | |||||
Short-Term Debt [Line Items] | |||||
Debt instrument, interest rate | 1.50% | 2% | |||
Commercial Coverage Solutions LLC [Member] | Oak Street Funding LLC [Member] | Term Loan [Member] | |||||
Short-Term Debt [Line Items] | |||||
Borrowings | $ 7,912,000 | ||||
Debt description | The borrowing rates under the Facility is a variable rate equal to Prime + 2.00% and matures 10 years from the closing date | ||||
Debt issuance costs | $ 181,125 | ||||
Debt instrument term | 10 years |
Warrant Liabilities (Details Na
Warrant Liabilities (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||
Jan. 05, 2022 | Dec. 22, 2021 | Mar. 31, 2022 | Jan. 31, 2022 | Feb. 28, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Common stock par value | $ 0.086 | $ 0.086 | $ 0.086 | ||||||
Number of shares issued | 138,000 | ||||||||
Preferred stock par value | $ 0.086 | $ 0.086 | $ 0.086 | ||||||
Unrealized losses | $ 17,652,808 | ||||||||
Unrealized gain | $ 14,572,126 | ||||||||
Derivative liability | $ 23,660,144 | 23,660,144 | 37,652,808 | ||||||
Derivative liability measured at fair value | 1,525,923 | ||||||||
Unrealized gain | (15,518,587) | 17,408,311 | |||||||
Series B Warrant Liability [Member] | |||||||||
Derivative liability | 23,080,682 | 23,080,682 | |||||||
Unrealized gain | (31,980,437) | ||||||||
Securities Purchase Agreement [Member] | |||||||||
Common stock par value | $ 0.086 | ||||||||
Aggregate purchase price of common shares, preferred shares and warrants | $ 20,000,000 | ||||||||
Securities Purchase Agreement [Member] | Private Placement [Member] | |||||||||
Warrant issued | 16,303 | ||||||||
Warrant exercise price | $ 61.35 | ||||||||
Derivative liability | $ 579,463 | 579,463 | |||||||
Warrant term | 5 years | ||||||||
Derivative liability measured at fair value | $ 1,525,923 | ||||||||
Unrealized gain | $ 946,461 | ||||||||
Securities Purchase Agreement [Member] | Series B Convertible Preferred Stock [Member] | |||||||||
Shares converted | 9,076 | ||||||||
Preferred stock par value | $ 0.086 | ||||||||
Share price per share | 1,000 | ||||||||
Preferred stock conversion price | 61.35 | ||||||||
Common Stock [Member] | |||||||||
Number of shares issued | 400 | 178,059 | 120,000 | ||||||
Common Stock [Member] | Private Placement [Member] | |||||||||
Number of shares issued | 178,059 | ||||||||
Common Stock [Member] | Securities Purchase Agreement [Member] | |||||||||
Warrant exercise price | $ 61.35 | ||||||||
Number of shares issued | 178,060 | ||||||||
Shares issued upon conversion | 147,939 | ||||||||
Common Stock [Member] | Securities Purchase Agreement [Member] | Maximum [Member] | |||||||||
Warrant issued | 651,997 |
SCHEDULE OF CONCENTRATIONS OF R
SCHEDULE OF CONCENTRATIONS OF REVENUES (Details) - Customer Concentration Risk [Member] - Revenue Benchmark [Member] | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | |
BlueCross BlueShield [Member] | |||
Concentration Risk [Line Items] | |||
Concentration of risk percentage | 10% | 22% | |
Priority Health [Member] | |||
Concentration Risk [Line Items] | |||
Concentration of risk percentage | 30% | 35% | |
LTC Global [Member] | |||
Concentration Risk [Line Items] | |||
Concentration of risk percentage | 25% | ||
Customer [Member] | |||
Concentration Risk [Line Items] | |||
Concentration of risk percentage | 10% |
SIGNIFICANT CUSTOMERS (Details
SIGNIFICANT CUSTOMERS (Details Narrative) | 12 Months Ended |
Dec. 31, 2021 | |
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer [Member] | |
Concentration Risk [Line Items] | |
Concentration Risk, Percentage | 10% |
SCHEDULE OF THE STOCK OPTIONS G
SCHEDULE OF THE STOCK OPTIONS GRANTED, FORFEITED OR EXPIRED (Details) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Equity [Abstract] | ||||
Number of Stock Options Outstanding, Outstanding at Beginning of Period | 10,928 | 15,594 | 15,594 | |
Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period | $ 232.50 | $ 231.45 | $ 231.45 | |
Weighted Average Remaining Contractual Life (years), Outstanding at End of Period | 2 years 4 months 13 days | 3 years 4 months 17 days | 2 years 7 months 9 days | 3 years 7 months 17 days |
Aggregate Intrinsic Value, Outstanding at Beginning of Period | ||||
Number of Stock Options Outstanding, Outstanding at End of Period | 10,928 | 15,594 | 10,928 | 15,594 |
Weighted Average Exercise Price, Outstanding at End of Period | $ 232.50 | $ 228.30 | $ 232.50 | $ 231.45 |
Aggregate Intrinsic Value, Outstanding at End of Period |
SCHEDULE OF NON - VESTED STOCK
SCHEDULE OF NON - VESTED STOCK OPTIONS (Details) - $ / shares | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Equity [Abstract] | ||||
Number of Non-vested Stock Options Outstanding, Outstanding at Beginning of Period | 3,587 | 10,636 | 10,636 | |
Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period | $ 227.10 | $ 200.85 | $ 200.85 | |
Weighted Average Remaining Contractual Life (years), Outstanding at ending of Period | 9 months 25 days | 2 years 4 months 2 days | 10 months 24 days | 2 years 6 months 10 days |
Number of Non-vested Stock Options Outstanding, Vested | ||||
Weighted Average Exercise Price Per Share, Vested | ||||
Weighted Average Remaining Contractual Life (years), Vested | ||||
Number of Non-vested Stock Options Outstanding, Outstanding at End of Period | 3,587 | 10,636 | 3,587 | 10,636 |
Weighted Average Exercise Price, Outstanding at End of Period | $ 227.10 | $ 223.05 | $ 227.10 | $ 200.85 |
SCHEDULE OF ASSUMPTION OF BLACK
SCHEDULE OF ASSUMPTION OF BLACK-SCHOLES OPTION PRICING MODEL (Details) - $ / shares | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Expected dividend | ||
Minimum [Member] | ||
Exercise price | $ 0.16 | $ 0.16 |
Expected term | 3 years 3 months | 3 years 3 months |
Risk-free interest rate | 0.38% | 0.38% |
Estimated volatility | 293.07% | 293.07% |
Option price at valuation date | $ 0.12 | $ 0.12 |
Maximum [Member] | ||
Exercise price | $ 0.26 | $ 0.26 |
Expected term | 3 years 9 months | 3 years 9 months |
Risk-free interest rate | 2.43% | 2.43% |
Estimated volatility | 517.13% | 517.13% |
Option price at valuation date | $ 0.27 | $ 0.31 |
EQUITY (Details Narrative)
EQUITY (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | ||||||
Mar. 31, 2022 | Jan. 31, 2022 | May 31, 2021 | Feb. 28, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2019 | |
Class of Stock [Line Items] | ||||||||
Preferred stock, shares authorized | 750,000,000 | 750,000,000 | 750,000,000 | |||||
Preferred stock, par value | $ 0.086 | $ 0.086 | $ 0.086 | |||||
Preferred stock, shares issued | 9,076 | 9,076 | 9,076 | 0 | ||||
Preferred stock, shares outstanding | 9,076 | 9,076 | 0 | |||||
Common stock, shares authorized | 133,333,333 | 133,333,333 | 133,333,333 | |||||
Common stock, at par value | $ 0.086 | $ 0.086 | $ 0.086 | |||||
Number of shares issued | 138,000 | |||||||
Issuance of common stock | $ 12,420,000 | $ 10,481,938 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares | ||||||||
Common stock, shares outstanding | 755,806 | 755,806 | 730,407 | |||||
Unrecognized compensation expense | $ 132,364 | $ 132,364 | $ 801,698 | |||||
Market value of share | $ 64.65 | $ 64.65 | $ 65.40 | |||||
Compensation expense | $ 739,960 | $ 246,966 | ||||||
Service Provider [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Fair value of options grants | 2,541,360 | |||||||
Employees, Directors, and Consultants [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Number of shares granted | 63,382 | 232,684 | ||||||
Three Employees [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Number of shares granted | 110,240 | |||||||
Compensation expense | 10,328 | |||||||
Two Employees [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Number of shares granted | 666,250 | |||||||
Compensation expense | $ 666,250 | |||||||
2019 Equity Incentive Plan [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Number of stock issued | 46,667 | |||||||
Common stock shares capital reserved for future issuance of shares | 31,027 | 31,027 | ||||||
2019 Equity Incentive Plan [Member] | Service Provider [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Fair value of options grants | $ 3,386,156 | |||||||
Common Stock [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Number of shares issued | 400 | 178,059 | 120,000 | |||||
Stock issued during period, shares, acquisitions | 40,402 | |||||||
Exercise of Series A warrants, shares | 25,000 | |||||||
Number of shares converted | 25,000 | (218,462) | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares | 400 | |||||||
Common Stock [Member] | Private Placement [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Number of shares issued | 178,059 | |||||||
Series A Warrant [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Exercise of Series A warrants, shares | 25,000 | |||||||
Warrants exercise price | $ 99 | $ 99 | $ 99 | |||||
Class of common stock warrant | 138,000 | 138,000 | ||||||
Warrants description | The warrants were recorded at a value per the offering of $0.15. The warrants may be exercised at any point from the effective date until the | |||||||
Warrants and Rights Outstanding, Term | 5 years | 5 years | ||||||
Warrant [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Exercise of Series A warrants, shares | 25,000 | |||||||
Series A Warrants [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Warrant shares outstanding | 113,000 | 113,000 | ||||||
JP Kush and Associates Inc [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Stock issued during period, shares, acquisitions | 995 | |||||||
Medigap Acquisition [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Stock issued during period, shares, acquisitions | 40,402 | |||||||
Reliance Global Holdings, LLC [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Debt converted outstanding | $ 3,800,000 | |||||||
Debt conversion, converted instrument, shares issued | 42,222 | |||||||
Conversion price per share | $ 90 | |||||||
Series A Preferred Stock [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Preferred stock, par value | $ 0.086 | $ 0.086 | ||||||
Series B Convertible Preferred Stock [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Preferred stock, shares authorized | 16 | 16 | ||||||
Series B Preferred Stock [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Preferred stock, par value | $ 0.086 | $ 0.086 | ||||||
Preferred stock, shares issued | 9,076 | 9,076 | 0 | |||||
Preferred stock, shares outstanding | 9,076 | 9,076 | 0 | |||||
Series A Convertible Preferred Stock [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Preferred stock, shares issued | 0 | 0 | 0 | |||||
Preferred stock, shares outstanding | 0 | 0 | 0 | |||||
Series C Prepaid Warrants [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Class of common stock warrant | 218,462 | |||||||
Series C Prepaid Warrants [Member] | Common Stock [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Class of common stock warrant | 218,462 | |||||||
Series D Prepaid Warrants [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Class of common stock warrant | 81,500 |
SCHEDULE OF CALCULATIONS OF BAS
SCHEDULE OF CALCULATIONS OF BASIC AND DILUTED EPS (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Earnings Per Share [Abstract] | ||
Net income (loss) | $ 9,340,000 | $ (613,926) |
Deemed dividend | (6,930,335) | |
Net income (loss), numerator, basic computation | 2,409,665 | (613,926) |
Recognition and change in fair value of warrant liabilities | (13,992,664) | |
Net income (loss), numerator, diluted computation | $ (11,582,999) | $ (613,926) |
Weighted average shares - denominator basic computation | 980,569 | 502,825 |
Effect of Series B warrant liabilities | $ 214,911 | |
Weighted average shares, as adjusted - denominator diluted computation | 1,195,480 | 502,825 |
Earnings (loss) per common share - basic | $ 2.46 | $ (1.22) |
Earnings (loss) per common share - diluted | $ (9.69) | $ (1.22) |
SCHEDULE OF ANTI-DILUTIVE SECUR
SCHEDULE OF ANTI-DILUTIVE SECURITIES IN WEIGHTED AVERAGE SHARES (Details) - shares | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Common Stock Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Weighted-average anti-dilutive securities | 10,928 | 10,928 |
Series A Warrant [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Weighted-average anti-dilutive securities | 113,000 | 138,000 |
Unvested Stock Awards [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Weighted-average anti-dilutive securities | 661 | 1,200 |
Conversion Series B Preferred Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Weighted-average anti-dilutive securities | 147,939 |
SCHEDULE OF FUTURE MINIMUM LEAS
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENT (Details) | Mar. 31, 2022 USD ($) |
Leases | |
2022 | $ 371,025 |
2023 | 439,110 |
2024 | 172,690 |
2025 | 112,923 |
2026 | 113,736 |
Thereafter | 268,197 |
Total undiscounted operating lease payments | 1,477,681 |
Less: Imputed interest | 172,402 |
Present value of operating lease liabilities | $ 1,305,279 |
LEASES (Details Narrative)
LEASES (Details Narrative) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Leases | ||
Operating Lease, Expense | $ 145,662 | $ 68,268 |
Weighted average remaining lease term | 4 years 4 months 28 days | |
Weighted average discount rate | 5.77% |
SCHEDULE OF EARN-OUT LIABILITY
SCHEDULE OF EARN-OUT LIABILITY (Details) - USD ($) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
Restructuring Cost and Reserve [Line Items] | ||
Beginning balance - January 1 | $ 3,813,878 | $ 2,931,418 |
Changes due to fair value adjustments | 407,071 | (278,102) |
Changes due to business combinations | 1,694,166 | |
Changes due to payments | (452,236) | |
Changes due to write-offs | (81,368) | |
Ending balance | 4,220,949 | 3,813,878 |
Commercial Solutions Of Insurance Agency LLC [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Beginning balance - January 1 | 81,368 | |
Changes due to fair value adjustments | ||
Changes due to business combinations | ||
Changes due to payments | ||
Changes due to write-offs | (81,368) | |
Ending balance | ||
Fortman Insurance Agency LLC [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Beginning balance - January 1 | 515,308 | 432,655 |
Changes due to fair value adjustments | 29,522 | 82,653 |
Changes due to business combinations | ||
Changes due to payments | ||
Changes due to write-offs | ||
Ending balance | 544,830 | 515,308 |
Southwestern Montana Insurance Center Inc [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Beginning balance - January 1 | 615,969 | 522,553 |
Changes due to fair value adjustments | 37,741 | 93,416 |
Changes due to business combinations | ||
Changes due to payments | ||
Changes due to write-offs | ||
Ending balance | 653,710 | 615,969 |
Altruis Benefits Consultants Inc [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Beginning balance - January 1 | 992,868 | 1,894,842 |
Changes due to fair value adjustments | (449,738) | |
Changes due to business combinations | ||
Changes due to payments | (452,236) | |
Changes due to write-offs | ||
Ending balance | 992,868 | 992,868 |
JP Kush and Associates Inc [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Beginning balance - January 1 | 1,689,733 | |
Changes due to fair value adjustments | 339,808 | (4,433) |
Changes due to business combinations | 1,694,166 | |
Changes due to payments | ||
Changes due to write-offs | ||
Ending balance | $ 2,029,541 | $ 1,689,733 |
COMMITMENTS AND CONTINGENCIES_2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Earn-out liabilities | $ 446,538 | $ 516,023 | $ 2,631,418 |
Revision of Prior Period, Adjustment [Member] | |||
Earn-out liabilities | 300,000 | ||
Previously Reported [Member] | |||
Earn-out liabilities | $ 2,931,418 |
INCOME TAXES (Details Narrative
INCOME TAXES (Details Narrative) | 3 Months Ended |
Mar. 31, 2022 USD ($) | |
Income Tax Disclosure [Abstract] | |
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent | 0% |
Income Tax Expense (Benefit) | $ 0 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Due to Related Parties | $ 343,000 | $ 354,000 |
Reliance Holdings [Member] | ||
Ownership percentage | 36% | 33% |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) - USD ($) | 3 Months Ended | ||
Apr. 26, 2022 | Mar. 31, 2022 | Mar. 31, 2021 | |
Subsequent Event [Line Items] | |||
Proceeds from Related Party Debt | $ 177,824 | ||
Subsequent Event [Member] | Term Loan [Member] | Oak Street Funding LLC [Member] | |||
Subsequent Event [Line Items] | |||
Debt description | The borrowing rate under the facility is variable and equal to Prime + 2.50%, except that during the initial period of the loan, the rate is Prime + 2.75%. The loan matures 10 years from the closing date and the service fee is .50% per year. | ||
Debt instrument term | 10 years | ||
Subsequent Event [Member] | Oak street lending [Member] | Term Loan [Member] | |||
Subsequent Event [Line Items] | |||
Principal amount | $ 6,520,000 | ||
Subsequent Event [Member] | APA [Member] | Barra and Associates LLC [Member] | |||
Subsequent Event [Line Items] | |||
Purchase price | 7,500,000 | ||
Working capital | 980,000 | ||
Subsequent Event [Member] | APA [Member] | Barra and Associates LLC [Member] | Oak street lending [Member] | |||
Subsequent Event [Line Items] | |||
Proceeds from Related Party Debt | 6,520,000 | ||
Subsequent Event [Member] | APA [Member] | Barra and Associates LLC [Member] | Paid at closing [Member] | |||
Subsequent Event [Line Items] | |||
Purchase price | 6,000,000 | ||
Subsequent Event [Member] | APA [Member] | Barra and Associates LLC [Member] | Payable in six months [Member] | |||
Subsequent Event [Line Items] | |||
Purchase price | 1,125,000 | ||
Subsequent Event [Member] | APA [Member] | Barra and Associates LLC [Member] | Payable over two years [Member] | |||
Subsequent Event [Line Items] | |||
Purchase price | $ 375,000 |